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ABSTRACT 
 
 
A novel orthomyxovirus was recently identified from pigs, with subsequent work 
suggesting the natural reservoir being bovine populations. The virus had genome 
characteristics most similar to influenza C viruses (ICV) but, due to the extent of 
sequence divergence, was proposed as a new genus, influenza D virus (IDV). Current 
literature on IDV has largely focused on the agricultural significance of the virus and 
provided evidence for the agricultural impact via observation of widespread prevalence 
and pathology in laboratory infected cattle. However, only one study, which identified 
1.3% seroprevalence in a small cohort, has addressed the zoonotic potential of IDV to 
date, despite evidence that the virus can infect multiple mammalian species. Regardless 
of zoonotic potential, it is clear that IDV have distinct host ranges from ICV but the 
molecular markers responsible are not known. In this dissertation we assessed the 
zoonotic potential of D/swine/Oklahoma/1334/2011 (D/OK), a representative IDV, and 
conducted studies to investigate receptor binding specificity, temperature sensitivity of 
replication kinetics, and pH of inactivation, all factors known to affect influenza A virus 
(IAV) host range.  
 
In order to better address zoonotic potential of D/OK we independently verified 
the high seroprevalence of D/OK in cattle in the US and found evidence of D/OK 
circulation in this animal population since at least 2003. We also identified 1% 
seroprevalence in a cohort of older humans who lived in a rural community with likely 
exposure to cattle. This seropositivity rate was not, however, elevated compared to earlier 
studies in populations with low exposure to cattle suggesting that the responses measured 
were not specific. Further analysis of the seropositive sera indeed found that the IDV 
seroreactivity was most likely due to cross-reactivity of antibodies induced after prior 
ICV infection. Despite our inability to identify strong serologic support for zoonotic IDV 
infection, we did show that D/OK was able to replicate and transmit by direct contact in 
ferrets and that it replicated robustly in differentiated human respiratory cells, both of 
which are consistent with an ability to replicate in humans for IAV. 
 
We next explored possible mechanisms for the differences in host range of IDV, 
which has multiple host species, and ICV, which infects primarily humans. 
Characterization of the HEF proteins of D/OK and a representative ICV demonstrated 
that D/OK exhibits altered receptor binding specificity and replicates at higher 
temperatures than ICV although it does bind receptors present in the human respiratory 
tract. Using virus-like particles with mutant hemagglutinin-esterase fusion (HEF) 
proteins, we found that the differences in receptor binding of D/OK were at least partially 
attributable to residues F143, W201, and F256 that line the putative receptor binding 
pocket. Surprisingly, we also found that, unlike other orthomyxoviruses, the replication 
of D/OK was not affected by prior incubation at low pH, raising the possibility that its 
replication might be pH independent. 
 
Reassortment of orthomyxoviruses is a known mechanism of pandemic 
emergence of IAV and an informal proxy for genus distinction with viruses from distinct 
 vi 
genera considered unable to successfully reassort. Contradictory to published data using 
conventional approaches we found that, using reverse genetics to force reassortment, 
D/OK genes could complement each of the corresponding genes from ICV and viable 
reassortants were produced. It is unclear, however, the biologic impact of these 
reassortments. The answer to this and other aspects of our work will require a resolution 
to the current US Governments pause on gain-of-function research. This observation 
does, however, bring into question the validity of classification of a new influenza genus 
despite IDV exhibiting the phylogenetic and antigenic divergence used to distinguish a 
novel genus.  
 
Together the evidence described in this study show that D/OK is widespread in 
cattle and has characteristics consistent with a zoonotic potential, although we were 
unable to find convincing evidence for such transmission in a small cohort of humans. 
We did find that D/OK has many features such as host range, receptor usage, sensitivity 
to pH, and optimal replication that are distinct from ICV and, we propose, supports its 
classification as a new genus with the orthomyxovirus family. Continued surveillance and 
investigation of host species barriers is necessary to further address the public health risk 
presented by this novel virus. 
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CHAPTER 1.    INTRODUCTION 
 
 
Introduction to Influenza Viruses 
 
 
Taxonomy 
 
Influenza viruses are included in the Orthomyxoviridae family and divided into 
three genera, Influenzavirus A, Influenzavirus B, and Influenzavirus C. Other genera in 
this family include Isavirus and Thogotovirus (1,2). Influenza A viruses (IAV) can be 
further classified by serotype according to the two surface glycoproteins 
(hemagglutinin and neuraminidase) expressed. There are 18 hemagglutinin (HA) and 
11 neuraminidase (NA) serotypes of IAV (3,4). There is only 1 serotype for influenza 
B viruses (IBV) with two evolutionary lineages, the B/Victoria/2/87-like and 
B/Yamagata/16/88-like lineages (5). The single serotype of influenza  C viruses (ICV) 
has six evolutionary lineages: C/Taylor/1233/47-like, C/Yamagata/26/81-like, 
C/Kanagawa/1/76-like, C/Aichi/1/81-like, C/Sao Paulo/378/82-like, and 
C/Mississippi/80-like lineages (6–8). 
 
 
Genome 
 
Influenza viruses are characterized by a segmented genome comprised of 
negative-sense, single-stranded, RNA (1,2). The influenza genome is composed of 7 or 
8 RNA segments which encode the template for at least 9 proteins, depending on the 
genus (1,9,10). All influenza genera comprise the following 6 gene segments in 
decreasing order of gene size: the polymerase basic 2 (PB2), polymerase basic 1 
(PB1), polymerase acidic or polymerase 3 (PA/3), nucleoprotein (NP), matrix (M), and 
nonstructural (NS). In addition to the six commonly shared gene segments, IAV and 
IBV contain 2 segments corresponding to expression of two surface glycoproteins, HA 
and NA, for a total of 8 gene segments. ICV contain 7 total segments expressing only 
one surface glycoprotein, hemagglutinin-esterase fusion (HEF) (Figure 1-1).  
 
Each viral RNA (vRNA) segment is comprised of a gene flanked by noncoding 
regions of ribonucleotides on the 3’ and 5’ ends of each segment, which are essential 
for packaging of a complete genome (11). These noncoding sequences are highly 
conserved and specific to each genus (9). Specific differences in the sequence and 
length of the noncoding region have been identified between each genus with the 
shortest noncoding nucleotide length found on IAV gene segments (12). The length of 
the noncoding region appears to regulate viral protein translation in a genus specific 
manner (13). Furthermore, the noncoding regions exhibit partial complementarity in 
sequence leading to formation of secondary panhandle structures (9). Evidence exists 
to support the role of these secondary structures and overall length of the noncoding 
region in type specificity through formation of viral ribonucleoprotein (vRNP), 
initiation of replication/transcription, and viral packaging (14,15).   
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Figure 1-1. The seven gene segments of ICV. 
Reprinted with permission and under the terms of the Creative Commons Attribution 4.0 
International License. http://creativecommons.org/licenses/by/4.0/ Wang M, Veit M. 
Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus. Protein Cell. 
2016;7(1):28–45. Available from: "http://dx.doi.org/10.1007/s13238-015-0193-x 
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Structure 
 
Each influenza virus RNA segment is associated in a complex with the viral 
polymerase proteins and nucleoprotein which is referred to as the vRNP complex (1). 
The vRNP is packaged in a capsid composed of matrix 1 proteins (M1).  The 
assembled capsid is further enveloped which includes an integral membrane protein, 
matrix 2 (M2), which functions as a proton channel, and glycoproteins which protrude 
from the viral envelope to facilitate efficient binding to, entry into, and budding of 
progeny virions from the host cell (Figure 1-2).   
 
Internal Proteins. The proteins which comprise the vRNP include three 
polymerase proteins, PB1, PB2, and PA/3, and the NP. PB1, PB2, and PA/3 are 
encoded by vRNA segments 2, 1, and 3, respectively, and collectively form the viral 
polymerase complex which is responsible for replication and transcription of vRNA. 
Conserved nucleotide sequences in polymerase vRNA segments and amino acid motifs 
of the corresponding polymerase polypeptides suggest homologous function of each of 
the three polymerase subunits in IAV, IBV, and ICV (16).  
 
The PB1 polymerase subunit serves as the structural basis for the polymerase 
complex through association with the PA/3 subunit at its N-terminus and the PB2 
subunit at its C-terminus (17,18). Once assembled, the polymerase complex is 
recruited by NP to form the vRNP. The PB1 subunit then associates with vRNA 
terminal ends and initiates the process of vRNA replication and transcription. The PB1 
subunit contains a polymerase active site responsible for vRNA elongation during this 
process. 
 
The PB2 polymerase subunit contains a PB1interaction domain for association 
at the PB1 C-terminus, a nuclear localization signal, and a cap-binding domain 
(17,18). This subunit undergoes a conformational change induced by association of the 
PB1 protein with vRNA allowing it to recognize and bind the 5’cap on host pre-
mRNA which will then lead to “cap snatching” activity of the third polymerase 
subunit.  
 
The third polymerase protein expressed by IAV and IBV is called the PA 
protein due to the protein’s acidic pKa, 5.2 (16). The analogous protein expressed by 
ICV exhibits a neutral pKa, 7.2, and is thus referred to as P3. The PA/3 polypeptide 
sequence encodes a PB1interaction domain for association with the N-terminus of the 
PB1 polypeptide and an endonuclease domain (17,18).  The endonuclease activity of 
this subunit results in the “cap snatching” function of the polymerase after host pre-
mRNA 5’ caps are bound by the PB2 subunit. The 5’cap is then used by the 
polymerase complex to initiate transcription of viral mRNA. 
 
The three polymerase proteins comprise the complete polymerase complex 
which requires an additional protein, NP, to associate with vRNA. The NP protein 
promotes assembly of vRNP and, consequently, vRNA replication/transcription by 
association with the 3’ and 5’ noncoding regions of vRNA and recruitment of the   
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Figure 1-2. Comparison of IAV, IBC, and ICV structure. 
Proteins with homologous function are represented by the same symbol. 
Reprinted with permission and under the terms of the Creative Commons Attribution 4.0 
International License. http://creativecommons.org/licenses/by/4.0/ Wang M, Veit M. 
Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus. Protein Cell. 
2016;7(1):28–45. Available from: "http://dx.doi.org/10.1007/s13238-015-0193-x 
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polymerase proteins to the complex (1,13). Studies of transcription/replication 
competence using a chloramphenicol acetyltransferase (CAT) reporter gene flanked by 
viral noncoding nucleotides reveal that interaction of NP and the polymerase complex 
is highly specific and contributes to type specificity (12,19). Homologous interaction 
between NP and the polymerase complex is required for efficient 
transcription/replication of vRNA; however, the NP protein can exhibit some 
promiscuity of vRNA interaction, depending on the genus (19). The NP-polymerase 
complex of IAV is the most promiscuous, able to initiate replication/transcript ion of 
IAV, IBV and ICV RNA. The IBV polymerase complex is the most specific, able to 
efficiently replicate/transcribe only IBV RNA. Last, the ICV polymerase complexes 
efficiently utilize IBV and ICV but not IAV RNA.  
 
The last of the internal proteins are the NS proteins, NS1 and NS2. The primary 
function of the NS1 protein in all three genera is to inhibit anti-viral interferon (IFN) 
signaling (20,21). NS1 negatively regulates IFN signaling via two mechanisms: RNA-
dependent and RNA-independent mechanisms. The RNA-independent mechanism 
involves NS1 inhibition of retinoic acid-inducible gene I (RIG-I), the upstream 
activator of the IFN-beta promoter.  NS1 c-terminal end binds RIG-I and inhibits 
downstream activation of the IFN-beta promoter in response to RIG-I recognition of 
double stranded RNA and 5’-triphosphate RNA. ICV NS1 has a unique function in this 
pathway from that of IAV or IBV NS1 because the n-terminal region also binds RIG-I 
but has a stimulatory affect, activating the downstream IFN-beta promoter (21). The 
purpose of this mechanism is not well understood. In the RNA-dependent pathway of 
all three genera, NS1 inhibits RIG-I via RNA-binding activity which allows NS1 to 
sequester the RNA away from RIG-I binding. The NS1 protein is not incorporated into 
the virion during packaging of any of the three genera (2). NS1 exhibits another type 
specific function in ICV; the NS1 protein up-regulates splicing of M and NS pre-
mRNA whereas the NS1 of IAV has an inhibitory action (22). The importance of this 
function is proposed to be in the viral replication cycle. NS1 is translated from a 
colinear RNA transcript whereas pre-mRNA splicing leads to creation of the NS2 
transcript. In vivo quantitation of NS1 and NS2 protein levels reveal that both proteins 
reach maximum levels approximately 24 hours post-infection but that NS1 protein 
levels begin to wane earlier than NS2 levels, about 36 hours post-infection as opposed 
to 48 hours. Increased levels of NS1 have been proposed to contribute a positive feed-
back loops increasing splicing of mRNA, including NS mRNA resulting in reduced 
transcription of NS1 but increased production of NS2 transcripts. The NS2 polypeptide 
contains a nuclear export sequence and associates with the vRNP to assemble, 
transport to the cell cytoplasm, and virion assembly, as evidenced by its incorporation 
into the virion (23). 
 
Structural Proteins and Surface Glycoproteins. The vRNP is packaged in a 
protective viral capsid that is composed of M1 proteins. The capsid becomes 
enveloped during the process of viral budding. The viral membrane contains M2 
transmembrane ion channels and surface glycoproteins which are anchored to the viral 
membrane via a transmembrane domain and interact with M1 via the cytosolic tail.  
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The M1 and M2 proteins are encoded on the approximately 1.2Kb, colinear 
viral gene segment 7 (2). IAV and IBV translate the M1 protein from unspliced 
mRNA. ICV uses a different coding strategy for M1, which is translated from spliced 
mRNA. Spliced mRNA is the primary species produced from M gene mRNA in ICV 
infected cells due to the proposed role of ICV NS1 in mRNA splicing upregulation 
(24,25). The nascent mRNA has a splice site in the open reading frame which, when 
spliced, introduces a stop codon leading to translation of the M1 polypeptide. The M2 
protein is transcribed from unspliced mRNA (26). After translation, the M2 protein 
undergoes glycosylation, followed by peptide cleavage to produce the final integral 
membrane protein. 
 
The functions of both matrix proteins are analogous in IAV, IBV, and ICV 
(2,24).  The M1 protein is the most abundant viral protein and the primary component 
of the viral capsid, providing structural rigidity to and determining the morphology of 
the virion. It is also important in the budding process.  The M2 protein is an ion 
channel which promotes capsid uncoating after host cell infection and budding of 
progeny virions. After the virion has fused with the host cell membrane and 
endocytosed into the host cell, the M2 ion channel allows influx of ions from the 
maturing endosome into the virion, causing uncoating of the viral capsid and release of 
the vRNA into the host cell cytoplasm. The M2 protein is also involved in 
incorporation of vRNPs into the budding virions and exhibits pH modulating activity 
to prevent acid inactivation of the HA during endosomal transport for some IAV and 
IBV (2,27). 
 
Finally, the viral surface glycoproteins are transmembrane proteins present in 
the viral membrane which covers the viral capsid (Figure 1-3). For IAV and IBV, the 
viral glycoproteins are the HA and NA whereas ICV express a single glycoprotein 
called the HEF. The HA of IAV and IBV facilitates host cell receptor recognition and 
binding and fusion of the viral and host cell membranes during infection. Neuraminic 
acid is the host cell receptor recognized by IAV and IBV HA proteins. The NA surface 
glycoprotein possesses receptor destroying enzyme function to cleave the sialic acid 
receptor on the host cell and enable virion budding.  The HEF of ICV possesses unique 
properties from that of IAV and IBV receptors. Distinct from the sialidase function of 
the NA protein, the HEF protein possesses acetylesterase activity recognizing a 9-O 
acetylated sialic acid residue on the host cell membrane, as opposed to neuraminic 
acids in the case of the HA (10,28–31).  Once bound to the host cell receptor, the virus 
is endocytosed and the HEF facilitates fusion between the viral envelope and host cell 
membrane, via a hydrophobic fusion peptide in the protein stalk, achieving entry into 
the cell cytoplasm.  The final function of the HEF protein enables proper budding of 
progeny virions from the host cell. The esterase moiety cleaves the 9-O linked acetyl 
group from the cell receptor leaving a naked sialic acid residue on the host cell surface 
allowing release of progeny virions and prevention of host cell re-infection. 
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Figure 1-3. Similar overall structure of IAV HA and ICV HEF. 
Reprinted with permission and under the terms of the Creative Commons Attribution 4.0 
International License. http://creativecommons.org/licenses/by/4.0/ Wang M, Veit M. 
Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus. Protein Cell. 
2016;7(1):28–45. Available from: "http://dx.doi.org/10.1007/s13238-015-0193-x 
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Influenza Virus Reassortment 
 
The segmented structure of the influenza genome necessitates proper packaging 
of all gene segments for production of a fully infectious virion. Packaging of each 
gene segment is dependent upon recognition of the 3’and 5’ noncoding region of RNA 
by NP for formation of vRNP complexes and assembly into the virion (19).  This 
system of genome packaging allows for reassortment of compatible viruses during co-
infection of the same host cell (32). However, compatibility of the 3’ and 5’ noncoding 
regions of each gene segment between the co-infecting virus strains are required for 
genome packaging and reassortment (11,15).   
 
 
Host Range 
 
Viruses in the genera IAV, IBV, and ICV have various host ranges but all 
genera include viruses that can infect humans. IAV circulate in a wide range of avian 
and mammalian hosts in addition to humans which includes waterfowl, terrestrial 
birds, swine, horse, dog, and seals (2). Furthermore, wild waterfowl are the natural 
reservoir for all subtypes of IAV and are thought to be the source of IAV in other 
animal species, making IAV the only influenza genus with an animal host reservoir. 
Yearly migration patterns of wild waterfowl maintain species transmission of IAV to 
other avian and mammalian hosts. With its large animal reservoir, distinct animal IAV 
can reassort with those IAV that are already human-adapted. Although the phenotype 
of their novel progeny is currently unpredictable, zoonotic transmission, in the case of 
the 1918 pandemic, and reassortment of animal influenza A viruses with distinct 
human-adapted influenza A viruses has yielded pandemic viral progeny in the cases of 
the 1957, 1968, and 2009 pandemics.  IBV and ICV, on the other hand, circulate only 
in humans with occasional reverse zoonosis transmission of IBV to seals and ICV to 
pigs (33,34). However, those IBV and ICV isolated from animals were of human 
lineage and represent sporadic reverse zoonosis, not a distinct lineage maintained in an 
animal host reservoir. Both genera, as a consequence of their single host reservoir in 
humans, have not produced pandemic reassortant progeny as observed over the past 
100 years.  
 
In humans, IAV and IBV cause seasonal outbreaks associated with mild to 
severe upper respiratory disease. ICV is also endemic in the human population but 
primarily causes mild disease in children. An estimated 60% of children are exposed to 
ICV by 4 years of age (35). Further, ICV is widespread in the United States where 96% 
of adults, 20-30 years of age, possess antibody titers against ICV (36).  ICV, due to the 
mild presentation of their associated disease in children, are not included in clinical 
diagnostics of patients with influenza-like symptoms (37). This lack of investigation 
exists despite the high prevalence of infection by ICV in humans, as identified by a 
limited number serological surveys conducted, and 30% of ICV infected infants 
requiring hospitalization (38). Moreover, 72% of hospitalized children exhibit more 
severe respiratory symptoms with high risk of complications such as influenza 
associated pneumonia (38–40). This evidence may suggest that ICV infection in 
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children is more severe than previously reported and argues the merits of more 
thorough surveillance of ICV. 
 
 
Influenza Virus Classification 
 
 
Classification Based on Antigenicity and Sequence Homology 
 
Taxonomic classification of influenza viruses is based, in part, upon antigenic 
differences of the internal proteins, M1 and NP. Although some variation of antigenic 
sites has been identified in the M1 and NP of IAV through analysis with monoclonal 
antibody panels, the two internal proteins are largely considered to be antigenically 
stable (41).  Similar analysis of the ICV M1 and NP proteins failed to identify 
antigenic differences with a monoclonal antibody panel in either protein from 
numerous ICV isolated over a 40 year period. The internal M1 and NP proteins of ICV 
are considered to be more antigenically stable than IAV or IBV proteins (42). 
 
 A more recent approach to taxonomic classification has focused on gene 
sequencing of the M, NP, and the most conserved protein, PB1 (16). The amino acid 
sequence of the PB1 protein is highly conserved within genera with 90% or higher 
homology between IAVs. However, there is much less conservation between viruses of 
different genera.  For example, the amino acid sequence of ICV PB1 proteins exhibit 
only 40% homology with IAV and IBV PB1 proteins.  Furthermore, the polypeptide 
sequences of the M1 and NP proteins share >85% intragenic homology but less, ~30%, 
intergenic homology (43).  
 
IAV are further classified by subtype, which is determined by the viral surface 
glycoproteins expressed by each strain. The multiple animal hosts of IAV in 
combination with evolutionary pressure applied by host immune systems have led to 
evolution of multiple subtypes of the surface glycoproteins. The HA and NA exhibit 
approximately 49% and 50% homology between IAV subtypes, respectively (44). IBV 
and ICV lack multiple host species and do not exhibit multiple subtypes. The 
homology between the single IBV HA and NA and IAV HA and NA subtypes share 
25% and 30% identity, respectively. 
 
 
Influenza Virus Reassortment 
 
Reassortment compatibility is determined, in part, by the length of and the 
secondary structure formed by the terminal noncoding regions of influenza RNA 
segments. These noncoding regions are highly conserved on the 3’ and 5’ terminal 
ends of each RNA segment and reassortment occurs frequently between strains of 
compatible type. Reassortment between influenza virus strains of different genera has 
not been observed in nature. 
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Identification of a Novel Influenza Virus 
 
 
Genetic and Antigenic Characterization 
 
In 2011, Newport Laboratories (a livestock diagnostic laboratory in 
Worthington, MN) isolated a virus from a clinically sick pig in Oklahoma (43).  A 
novel influenza C-like virus was identified based upon phylogenetic and functional 
analysis and was designated C/swine/Oklahoma/1334/2011 (C/OK). The novel virus 
genome shared only 50% identity with previously described ICV although C/OK 
contains 7 RNA segments, all of which align with the RNA segments of human ICV 
(Figure 1-4). Additionally, the HEF protein demonstrated esterase function but not 
neuraminidase activity. C/OK was found to be antigenically distinct from human ICV 
by hemagglutination inhibition and agarose gel immunodiffusion assay (43,45).  
Further, efforts to assess reassortment of C/OK with human-adapted ICV failed to 
identify reassortant progeny after in vitro co-infection between the two viruses. 
 
The finding that C/OK was phylogenetically and antigenically distinct from 
human ICV evoked suggestions that it may represent a novel ICV subtype or a new 
genus (43,45). 
 
The Case for Classification of Bovine Influenza as a New Genus 
 
C/OK was classified as an ICV upon initial evaluation based upon presence of 
seven RNA segments which aligned most closely to ICV genes in phylogenetic 
analysis, including the HEF gene, and detection of esterase but not neuraminidase 
activity (43).  However, overall sequence similarity of the C/OK genome was only 
50% to that of human ICV. Furthermore, the HEF polypeptide of C/OK exhibited 
similar sequence identity to the HEF of human ICV as the HA of IAV subtypes. This 
evidence suggested that antigenic characterization of C/OK should be conducted to 
evaluate C/OK for classification as a novel ICV subtype or new genus. 
 
The antigenic relationship of C/OK to IAV, IBV, and ICV was addressed by 
hemagglutination inhibition and agarose gel immunodiffusion assay using polyclonal 
ferret antibodies generated against viruses of each genus.  Two human ICV strains were 
included in the analysis and, although antigenically distinct from IAV and IBV, were 
antigenically indistinct from each other. Conversely, C/OK was antigenically distinct 
from all IAV, IBV, and ICV strains tested by these assays. C/OK antigenicity was not 
assessed in the context of taxonomic classification, by anti-M1 or anti-NP monoclonal 
antibodies, however, sequence analysis of C/OK M1, and NP proteins does predict 
antigenic distinctions.  
 
The nucleotide sequences of the M and NP genes were used to predict the 
amino acid sequence of the translated polypeptides, based upon homologous ICV 
protein sequences. The M gene, due to unpredictability of post-translational splicing 
sites in the M gene polypeptide, the nascent polypeptide sequence, called p42, was   
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Figure 1-4. The phylogenetic relationship of C/OK with human ICV. 
Reprinted with permission and under the terms of the Creative Commons Attribution 
Non-Commercial License. Hause BM, Ducatez M, Collin EA, Ran Z, Liu R, Sheng Z, et 
al. (2013) Isolation of a Novel Swine Influenza Virus from Oklahoma in 2011 Which Is 
Distantly Related to Human Influenza C Viruses. PLoS Pathog 9(2): e1003176. 
doi:10.1371/journal.ppat.1003176 
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used for comparison of amino acid sequences. The maximum sequence identity of 
C/OK p42 and NP polypeptides to homologous ICV proteins were 38% and 39%, 
respectively; both demonstrating similar intergenic divergence as seen between ICV 
and IAV.  Furthermore, analysis of the most conserved influenza protein, PB1, 
determined that the C/OK protein shared a maximum of 72% identity with the ICV 
PB1, higher than the 61% intergenic homology of IAV and IBV PB1 but lower than 
the 90% intragenic homology of IAV strains.  
 
Despite the low overall sequence similarity of C/OK to ICV, the 3’ and 5’ 
noncoding regions of the vRNA segments differ by only one nucleotide each. Previous 
mutagenesis studies whose results suggest that influenza type compatibility is largely 
determined by noncoding region length and formation of secondary structures for 
association with NP would predict that a single nucleotide difference would not lend to 
segment incompatibility. Even so, ICV failed to produce reassortant progeny with 
either of two ICV strains after co-infection in cell culture suggesting type 
incompatibility of the two viruses.  
 
C/OK demonstrates the extent of phylogenic and antigenic differences seen 
between IAV, IBV, and ICV genera and noncoding RNA incompatibility with ICV. It has 
been proposed that C/OK, and related influenza strains, should be classified as a novel 
genus titled influenza D virus (IDV) (43,45). We will refer to C/OK, heretofore, as 
D/OK. 
 
 
Surveillance and Pathogenicity 
 
Sero-surveillance of American swine and cattle identified antibodies reacting 
with D/OK in approximately 9.5% of pigs and up to 90% of cattle (43,45,46), with 
detection of D/OK vRNA in 18% of cattle by reverse transcription-realtime PCR 
analysis. However, only 1.3% seroprevalence was identified in a human cohort of 316 
individuals (43) Domestic sheep and goats have been identified as possible hosts as well 
(47). Cattle are now believed to be the major reservoir for this virus due to high 
seroprevalence in the United States and the evolution of two phylogenetically and 
antigenically distinct clades represented by, provisionally named, D/OK and 
D/bovine/Oklahoma/660/2013 (45,48,49). Evidence of D/OK-like bovine viruses have 
been reported in China, France, and Italy, as well (50–52).  
 
Initial characterization of the pathogenicity of IDV found that it was 
transmissible by direct contact but not aerosol droplet contact in experimentally 
infected pigs, ferrets, and guinea pigs (43,53).  All inoculated pigs, ferrets and guinea 
pigs seroconverted. All direct contact ferrets and guinea pigs and some direct contact 
swine seroconverted. No animals exhibited clinical signs. A unique observation of the 
guinea pig model was evidence of IDV replication in upper and lower respiratory 
tracts, as opposed to only upper respiratory tract of pigs and ferrets. Last, the 
agricultural impact of D/OK was demonstrated by findings of direct contact 
transmission in cattle with mild respiratory signs and some disease pathology (54). 
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Research Aims 
 
A novel influenza virus was isolated in 2011 from swine exhibiting clinical 
respiratory symptoms and was later determined to represent a novel genus of swine and 
bovine influenza viruses, IDV. Although low seroprevalence was found in a small 
cohort of 316 individuals, IDV can cross species barriers. However, current literature 
has primarily focused on prevalence in cattle and the agricultural impact of IDV and 
lacks investigation of zoonotic potential in order to address potential impact on public 
health as well. 
 
In this study, we proposed a range of experimental approaches to assess the 
potential public health risk posed by IDV. We investigated prevalence of D/OK-related 
viruses in cattle and humans in the United States and provide evidence of zoonotic and 
reassortment potential. Further, we examined multiple mechanisms which could impact 
IDV host species restrictions and confer altered host range compared to human ICV. 
 
 
Hypothesis 
 
IDV is widespread in cattle in the US and may infect humans based upon 
serosurveillance in a small human cohort and a ferret transmission study. We 
hypothesize that IDV, although distinct from ICV in many properties, represents a 
newly identified source of zoonotic infection. 
 
To build upon preliminary research, we propose the following specific aims. 
 
 
Specific Aims 
 
Part 1. Investigate zoonotic potential of D/swine/Oklahoma/1334/2011 
including prevalence in cattle and evidence of human infections.  
 
Part 2. Evaluate the host range and receptor tropism of 
D/swine/Oklahoma/1334/2011 and a human-adapted influenza C virus.  
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CHAPTER 2.    SEROLOGICAL SURVEILLANCE OF D/OK AND 
ASSESSMENT OF ZOONOTIC AND REASSORTMENT POTENTIAL 
 
 
Introduction 
 
Current data concerning D/OK strongly supports a model where IDV is a virus of 
ruminants with high prevalence in cattle in the United States as well as France, Italy, and 
China (50–52). Transmission by direct contact of IDV in cattle and seroprevalence in 
adolescent cattle in Mississippi feedlots demonstrates a clear agricultural impact of IDV 
in that species (54). Furthermore, IDV can cross species barriers into swine and the 
potential for agricultural impact in swine and other agricultural animal species exists.  
 
The primary focus of D/OK studies have been concerned with the agricultural 
relevance of the virus and, despite widespread prevalence in American cattle and 
evidence of transmission between animal species, the potential for zoonotic infection is 
unclear. Supporting a zoonotic potential of IDV were previously published data from a 
seroprevalence study amongst a small number of individuals from the general population 
in Canada and the United States (44). In this study an IDV seroprevalence of 1.3% was 
detected. This level of seroprevalence in members of the general population suggests that 
IDV infection is not uncommon which is difficult to reconcile with the virus never being 
identified in humans. It is also unclear, despite lack of cross reactivity with post-infection 
ferret antiserum, whether prior repeated exposure to ICV could result in antibodies able 
to cross react with IDV. With these caveats and lack of data present, we sought to provide 
a more robust determination of the serologic and biologic evidence for a zoonotic threat 
from IDV, specifically D/OK. 
 
We approached this task by providing a more robust temporal and spatial 
evaluation of IDV serology in bovine populations and by examining evidence for IDV 
exposure in a cohort of individuals with elevated contact with dairy cattle.  We 
hypothesized that, should IDV infect humans, this population would have elevated 
seroprevalence levels. In order to better interpret these data we also utilized multiple 
assays and sought to determine true levels of ICV and IDV cross reactivity in human 
sera. We also investigated IDV replication in models that have been used to assess 
pandemic risk in IAV, namely, ferret transmission and in vitro replication in human 
respiratory epithelial cells. Lastly, as reassortment between IAV viruses has been 
associated with phenotypic changes and host shifts, we investigated the compatibility of 
IDV and ICV gene segments in reverse genetics based reassortment studies. We find that 
while evidence for human infection with IDV is limited, the virus has a number of traits 
consistent with that of a virus with an inherent zoonotic risk. 
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Materials and Methods 
 
 
Cell Culture 
 
Swine testicle (ST), human embryonic kidney 293T (293T), and Madin-Darby 
Canine Kidney (MDCK) cells were obtained from the American Type Culture Collection 
(Manassas, VA). ST and 293T cells were maintained in Dulbecco modified Eagle's 
medium (DMEM; Invitrogen Corporation, Grand Island, NY) and minimum essential 
medium (MEM; Corning, Manassas, VA) respectively, supplemented with 5% fetal 
bovine serum (FBS; HyClone, Logan, UT) and antibiotics-antimycotic (Sigma, St. Louis, 
MO; 100 U/ml penicillin, 100 µg streptomycin, and 0.25 µg amphomycin per ml). 
MDCK cells were maintained in MEM supplemented with 5% FBS, 1x MEM vitamin 
solution (Invitrogen Corporation, Grand Island, NY), 200mM L-Glutamine (Invitrogen 
Corporation, Grand Island, NY) and antibiotics-antimycotics.  Normal human bronchial 
epithelial (NHBE) cells were purchased from MatTek Corporation (EpiAirway AIR-100; 
Bratislava, Slovak Republic) in 6 well, trans-well tissue culture plates which had been 
differentiated for 28 days at the air-liquid interface.  Upon arrival, cells were maintained 
for three days prior to virus infection with AIR 100 complete growth media (MatTek, 
Bratislava, Slovak Republic) according to manufacturer’s instructions.  All cell culture 
was incubated at 37oC and 5% CO2. 
 
 
Viruses 
 
Viruses used in this study D/swine/Oklahoma/1334/2011 (D/OK), 
C/Victoria/1/2011 (C/Victoria), C/Kowloon/V09-2204956/2009 (C/Kowloon), and 
reverse genetics rescue virus C/JJ/1950 (rg-C/JJ) were provided by: Newport Laboratory 
(Worthington, MN) , Ian Barr (World Health Organization Collaborating Centre for 
Reference and Research on Influenza, Melbourne, Australia), Janice Lo (Department of 
Health, Hong Kong Special Administrative Region, China), and Reinhard Vlasak 
(University of Salzburg, Salzburg, Austria), respectively. D/OK virus stocks were 
clarified from supernatant of infected ST cells replicated in the presence of 0.1 µg/ml of 
L-1-(tosyl-amido-2-phenyl)ethyl chloromethyl ketone (TPCK)–treated trypsin (TPCK; 
Worthington Diagnostics) after five days and at 37oC. C/Victoria and C/Kowloon stocks 
were propagated after approximately 5 serial passages in the amniotic cavity (each 
passage virus diluted 1:1 with sterile allantoic fluid) of 7-10 day old embryonated eggs at 
33oC for 5 days followed by an additional 5 passages of undiluted virus in allantoic 
cavities.  rg-C/JJ stocks were rescued by reverse genetics (see below) and propagated in 
allantoic fluid of 7-10 day old embryonated eggs at 33oC for 5 days. A/Brisbane/59/07 
(A/Brisbane) was propagated in allantoic fluid of 7-10 day old embryonated eggs at 37oC 
for 3 days. 
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Human Subjects 
 
To assess prior bovine influenza virus exposure, banked sera collected from adults 
aged ≥50 years previously enrolled in an influenza vaccine immune response study at 
Marshfield Clinic Research Foundation (WI) were evaluated. Participants of the study 
were residents of a community with a high probability of dairy farm exposure. A total of 
741 pre- and post- vaccination samples from participants were available from four 
separate seasons between 2008-2009 and 2012-2013 for testing. The pre- and post- 
vaccination titers per participant were not determined due to de-identification of samples. 
 
 
Bovine Sampling 
 
Banked bovine sera from Ronald Schultz (University of Wisconsin-Madison, 
Madison, WI), collected from 837 animals between 1977 and 2014 were tested for D/OK 
antibody titers.  
 
 
Virus Quantitation 
 
Hemagglutination Assay (HA). HA titers were determined by incubation of 2-
fold, serially diluted virus with 0.5% chicken red blood cells (cRBC) for 30 minutes at 
room temperature. HA titers were determined as the highest dilution to fully agglutinate 
red blood cells (RBC).  
 
50% Tissue Culture Infectious Dose (TCID50). TCID50 was performed by 
infection of MDCK cells, washed twice with phosphate buffered saline (PBS), for 1 hr. 
with virus serially diluted in cell culture media (55). Virus was then removed and 
replaced with infection media containing 0.1ug/ml TPCK.  C/Victoria, C/ Kowloon, and 
rg-C/JJ were incubated at 33oC and D/OK at 37oC for 5 days. Wells were read for 
agglutination following the addition of 0.5% cRBCs and incubation at room temperature 
and TCID50 titers were determined according to the Reed and Muench method (56). 
 
 
Sera Treatment 
 
RDE Treatment. Bovine and human sera were treated with receptor destroying 
enzyme (RDE; Denka Seiken Co., Ltd., United Kingdom) at 37oC for 18 hours, 
inactivated for 1 hour at 56oC, and used at 1:10 dilution.  
 
RBC Preadsorption. RBC preadsorption of bovine sera was performed to 
remove factors which might contribute to non-specific agglutination of RBC in a 
hemagglutination inhibition assay, described below, contributing a “false negative” result 
for antibody titers. Treatment was performed by dilution of RDE treated sera at 1:20 with 
packed cRBCs and incubated for one hour at 4oC. Samples were then centrifuged at 447 x 
g for five minutes and sera collected for subsequent analysis. 
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Trypsin Periodate Treatment. Trypsin periodate treatment was performed 
according to World Health Organization Manual on Animal Influenza Diagnosis and 
Surveillance (57). Briefly, sera were inactivated with trypsin solution at 56oC for 30 min. 
This was followed by addition of 0.011M metapotassium periodate and then 1% glycerol 
saline for 15 minutes at room temperature, each, before final dilution of sera of 1:10 with 
1x PBS.   
 
Virus Preadsoprtion. Virus preadsorption of human sera was performed to 
assess cross-reactivity of human ICV derived antibodies to D/OK. Enzyme immunoassay 
(EIA)/radioimmunoassay (RIA) plates (Costar, Corning, NY) were plated with 50ul 
antigen (normalized to 32 HA titer) or uninfected egg allantoic fluid overnight at 4oC. 
Plates were then washed with PBS with 0.05% Tween (PBST) and blocked with PBS 
with 5% bovine serum albumin (BSA) for 2 hours at room temperature before addition of 
sera and incubated overnight at 4oC. Preadsorbed sera was removed and used for 
subsequent analysis. 
 
 
Serology 
 
Hemagglutination Inhibition. Hemagglutination inhibition (HI) assay was 
performed using 0.5% cRBCs and RDE treated sera (57). Sera were serially diluted in 
PBS and incubated with a concentration of virus equal to four agglutinating doses for 1 hr 
at room temperature. Next, 0.5% cRBCs were added to each well and incubated for 30 
min. at room temperature and read. Titers were determined as the reciprocal of the 
highest agglutination inhibiting dose (HIU). Only HAI titers ≥ 40 were considered 
positive.  
 
 Microneutralization Assay. Microneutralization (MN) assays were performed by 
incubation of 2-fold serially diluted, RDE-treated sera with 2x103 TCID50/ml virus for 30 
minutes at room temperature prior to addition to MDCK cells washed twice with 1x 
PBS.  Titers were determined as the reciprocal of the highest TCID50 virus titer.   
  
ELISA. Virus stock was inactivated for use in ELISA by addition of 1:2000 β -
propiolactone (BPL) and incubated for 72 hours at 4oC.  Virus inactivation was verified 
by a HA titer of 0 after passaging twice in five eggs with 100ul each of undiluted BPL-
treated virus and incubated for 5 days at 33oC.  
 
ELISA was performed with 1:16 dilution of BPL-treated virus (normalized to 32 
HA titer) or allantoic/uninfected cell supernatant control in coating buffer.  EIA/RIA 
plates (Costar, Corning, NY) were plated with 50ul antigen overnight at 4oC. Plates were 
then washed with PBST and blocked with PBS with 5% BSA for 2 hours at room 
temperature before addition of serially diluted sera and incubated overnight at 
4oC.  Plates were again washed with PBST and incubated for 2 hours at room temperature 
with 1:1000 anti-human IgG –Alkaline Phosphatase (Jackson Immuno Research 109-
055-008). Plates were washed once more and developed for 45 minutes in dark room 
with alkaline phosphatase substrate (pNPP Microwell Substrate System: KPL #50-80-
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00). The reaction was stopped with 0.5% EDTA and plates were read at 410nm on 
microplate reader. 
 
 
Ferret Transmission 
 
 Ferret transmission experiments were performed by infection of three ferrets each 
with D/OK, C/Victoria, and C/Kowloon. Ferrets were anesthetized with 200cm3/min of 
oxygen isoflurane inhalation followed by intranasal instillation of 106 TCID50 virus. 
Twenty-four hours post infection, naïve contact ferrets were introduced. Nasal wash was 
collected on days 2, 4, 6, 8, 10, and 12 post infection with 1ml PBS after intramuscular 
administration of ketamine. Post-infection serum was collected on day 14 post infection. 
Euthanasia was performed by intravenous administration of barbiturate overdose. 
Euthanasia of the animals for tissues was performed according to the recommendations of 
the Panel of Euthanasia of the American Veterinary Association. 
 
 
Normal Human Bronchial Epithelial Replication Kinetics 
 
Virus replication kinetics was performed in NHBE cells which serve as an in vitro 
model for influenza virus replication in the human respiratory system. (58). NHBE cells 
in 6-well plate inserts were infected with D/OK, C/Victoria, C/Kowloon, or rg-C/JJ at a 
multiplicity of infection (moi) of 0.01 for 1 hour at 33oC after washing cells 10 times 
with 1x PBS to remove mucus.  After 1 hour absorption, apical media was removed and 
cells exposed at the liquid-air interface.  At each time point, the basal media was replaced 
with 1ml complete media, supplemented with 0.2% BSA and 300ul were added to the 
insert.  Cells were incubated with apical and basal media and both were collected after 30 
minutes and stored at -80oC until titrated.  Finally, the basal media was replaced with 1ml 
complete media so that cells were always exposed to the basal liquid-apical air 
interface.  Samples were collected at 1, 24, 48, 72, 96, and 120 hours post infection and 
viral titers were determined as TCID50/ml.  The experiment was performed twice with 
triplicate wells of each virus infection. 
 
 
Reverse Genetics Plasmid Construction 
 
The bi-directional cloning plasmid, pPMV, and seven bi-directional C/JJ/1950 
gene pPMV plasmids for the rescue of reverse genetics virus were kindly provided by 
Reinhard Vlasak, University of Salzburg.  To prepare the D/OK reverse genetics plasmid 
system, D/OK viral RNA was extracted and purified by RNeasy Viral RNA extraction kit 
(Qiagen, CA).  Reverse transcription and amplification of each D/OK gene was 
performed by SuperScript® III One-Step RT-PCR System with Platinum® Taq High 
Fidelity (Invitrogen™) with gene specific primers. Gene specific primer design was 
executed using the Primer Design tool for In-Fusion® HD Cloning Kit 
(www.clonetech.com) for HEF, P3, PB1, and PB2 genes.  Cloning primers for NS, NP, 
and M genes were designed to include the terminal 25 nucleotides of each gene and the 
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restriction site sequence. Each gene was then ligated into the bi-directional pPMV 
cloning vector using the In-Fusion HD Cloning Kits (Clontech, Mountain View, CA) 
according to manufacturer’s instructions or T4 DNA Ligase (NEB, Ipswich, MA). The 
pPMV plasmid and NP, NS, and M amplified genes were cut using the Bsmb1 restriction 
enzyme (NEB, Ipswich, MA). 
 
 
Virus Rescue 
 
Reverse genetics virus rescue was performed with modifications as previously 
described for the assessment of virus reassortment compatibility (59).  First, a 1:4 co-
culture of MDCK:293T cells were plated in 6-well plates at 37oC overnight. The 
following day, one microgram of each of the seven gene plasmids was equilibrated with 
16ul TransIT-LT1 Transfection Reagent (Mirus, Madison, WI) in 200ul of optimized 
MEM (Opti-MEM) (Invitrogen Corporation, Grand Island, NY) for 45 minutes at room 
temperature.  The transfection mixture was then brought to 1ml total volume and 
transferred to the MDCK:293T co-culture and incubated at 33oC overnight. On day 1 
post-transfection; the inoculation media was replaced with 1ml Opti-MEM supplemented 
with 200mM GlutaMAX supplement (Thermofisher Scientific, Carlsbad, CA) and 
antibiotics-antimycotics. On day 2 post-transfection an additional 1ml transfection media 
with 1ug/ml TPCK was added to each transfection well at 33oC. On day 4 post-
transfection; the culture supernatant was collected and HA titers of rescue virus were 
determined with 0.5% cRBCs.  Transfection supernatant was passaged twice in MDCK 
cells to obtain a virus stock. 
 
 
Statistical Analysis  
 
HI, MN, and ELISA antibody titers were compared by Spearman nonparametric 
correlation in Graphpad Prism 5 (GraphPad Software, Inc., CA).   
 
 
Results 
 
 
Serology of Historic Bovine Samples 
 
In consideration of the mounting evidence of D/OK prevalence in cattle, which 
suggests this species may serve as the host reservoir for IDV, we wished to establish a 
relative timeline of IDV introduction and prevalence in US cattle to better assess IDV 
exposure to humans. Specifically, we wished to determine IDV introduction and 
prevalence in cattle within a similar region of our subsequent human cohort. First, we 
used archived bovine sera to look for evidence of prior circulation of the virus in this 
host. Both objectives were addressed by determining D/OK HI titers in banked bovine 
sera. D/OK HI antibodies were undetectable in all bovine sera collected prior to 2003 but 
were present in 53% of sera collected after 2003 (geometric mean titer (GMT) 131.7, 
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95% CI [118.7, 146.1]) from various geographic regions in the United States (Figure 
2-1). Positive HI titers ranged from 40 to 1280 and similar results were obtained by MN 
assay (R= 0.8398, P<0.0001) (Figure 2-2). These results suggested that individuals in the 
United States were likely exposed to IDV since at least 2003. 
 
 
Geographic Distribution of IDV Seroprevalence 
 
Bovine sera used for surveillance was collected from across the United States. 
The majority of sera collected prior to 2003 originated from WI, TN, and AL (Table 
2-1). However, the origin of the rest of the historic sera was not provided. Sera collected 
after 2003 was collected from WI, NE, ND, SD, TX, and MS (Table 2-2).  Although the 
geographic distribution of sera collected prior to 2003 was different from that of sera 
collected after 2003, a number of sera from both groups were collected from WI. The 
observation that no D/OK sera was identified in WI prior to 2003 but almost 60% were 
positive after 2003 supports conclusions that the virus emerged in American cattle some 
time before 2003 and that individuals living in WI have been exposed to IDV for at least 
13 years. Furthermore, a small cohort of 23 sera collected from Chilean cattle in 2014 
had 9 (23.1%) seropositive samples demonstrating a geographic distribution of IDV 
spanning North and South America. This is the first report of IDV in South America. 
 
As non-specific inhibitors of hemagglutination are not uncommon in some animal 
species we re-ran the D/OK HI-positive, and a selection of D/OK HI-negative samples 
using alternative serum preparation strategies. Specifically, cRBC preadsorption, to 
remove any serum components able to bind to RBC, and trypsin periodate treatment of 
sera was conducted to address the possibility of non-specific interactions and confirmed 
the specificity of the HI results with no change in positive titers due to treatment or assay. 
RDE HI titers significantly correlated HI titers obtained after cRBC preadsorption (R= 
0.9559, P<0.0001) and HI titers after trypsin periodate treatment (R=0.4470, P=0.0251) 
(Figures 2-3 and 2-4).These results confirmed the widespread nature of IDV infection in 
US cattle and also showed that the virus was in this population at least as far back as 
2003 providing ample opportunity for exposure of humans to infected animals. 
 
 
D/OK Serological Surveillance in Likely Highly Exposed Individuals 
 
Having determined that seroprevalence of D/OK-like viruses was temporally and 
spatially widespread in US cattle we next sought to determine if the same was true in 
human exposed to these animals.  To assess D/OK seroprevalence in a high-risk human 
population, sera from older residents of a community with high probability of dairy farm 
exposure, and by inference, to IDV were used (Table 2-3). Sera were assessed for the 
presence of D/OK-reactive antibodies by HI and only 8 individuals were weakly 
seropositive (resulting in 1% seroprevalence) with a GMT of 46.57, 95% CI [39.07, 
55.50]. 
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Figure 2-1. D/OK-reactive antibodies as assessed by HI are undetected in bovine 
sera collected prior to 2003. 
The total number of D/OK HI positive sera is represented by the red bars and total 
number of negative sera is represented by the black bars. 
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Figure 2-2. D/OK MN titers statistically correlate to HI titers in bovine sera. 
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Table 2-1. Total bovine sera collected prior to 2003 by state. 
 
State Total Sera Tested 
WI 42 
TN 13 
AL 136 
Unknown 119 
 
 
 
 
Table 2-2. Seroprevalence of IDV, per state, collected after 2003. 
 
Data 
Representation 
State 
Total 
WI NE ND SD TX MS 
Positive/ 
total sera 
108/181  0/12  8/26  15/67  101/134  12/33  244/453  
Percent positive 59.7% 0.0% 30.8% 22.4% 75.4% 36.4% 53.9% 
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Figure 2-3. D/OK HI titers of bovine sera using RDE treated sera are not 
significantly different than RDE + RBC preadsorption treated sera.  
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Figure 2-4. D/OK HI titers of bovine sera using RDE treated sera are not 
significantly different than trypsin periodate treated sera. 
 
 
 
 
Table 2-3. The number of sera from individuals likely exposed to cattle which 
were tested for IDV antibodies by HI is listed by season. 
 
Season Total Sera Tested 
2008-2009 205 
2009-2010 251 
2011-2012 150 
2012-2013 135 
Total 741 
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Although it was previously shown that there was no serologic cross reactivity in 
HI between D/OK and ICV (which we confirmed below) using post infection ferret 
antiserum it was not clear if the same was true in human serum (43,45). Thus, we further 
tested the 8 HI-positive and 6 randomly selected HI-negative sera by HI, ELISA and MN 
assay (Figures 2-5, 2-6, and 2-7) for reactive antibodies to D/OK and a human ICV, 
C/Victoria. There was no statistical correlation between D/OK and C/Victoria positive/ 
negative titers or between D/OK titers determined by HI, MN, and ELISA assays (Table 
2-4 and 2-5). 
 
There were two possible explanations for the positive D/OK serum samples we 
tested. The first is that they represented true D/OK-like virus infection with the second 
being that the titers were simply due to cross reactivity due to repeated exposure to ICV.  
To determine if the titers we observed to D/OK were due to specific response or ICV 
cross reactive responses we preabsorbed positive samples with concentrated C/Victoria. 
We hypothesized that if the D/OK titers were specific then C/Victoria preadsorption 
would have minimal impact on D/OK titers. Conversely, if the D/OK titers were due to 
cross reactive responses then C/Victoria preadsorption would remove any D/OK 
reactivity. The latter was the case and C/Victoria preadsorption resulted in removal of all 
D/OK HI titers in previously positive samples. The one exception was sample 7 where 
preadsorption failed to even reduce C/Victoria titers (Table 2-6). In order to validate the 
specificity of the assay, we assessed antibody titers specific for an H1N1 IAV strain, 
A/Brisbane, after C/Victoria preadsorption as well.  While the A/Brisbane titers were too 
low in the D/OK HI positive samples to determine specificity, several D/OK HI negative 
sera, which had higher (up to 80 HIU) A/Brisbane specific titers, were similarly treated. 
As expected, C/Victoria preadsorption had minimal impact on A/Brisbane titers and a 
maximum of two-fold reduction was observed.   
 
We further investigated the cross reactivity of IDV and ICV using post-infection 
ferret antiserum generated in the ferret transmission study described later in this chapter. 
Such reagents are known to be more specific than human serum in regards IAV serology. 
We compared HI, MN, and ELISA titers of ferret polyclonal antibodies generated to 
D/OK and C/Victoria for cross-reactivity. As was seen in previous studies, there was no 
cross-reactivity detected by HI but MN and ELISA assays were able to pick up cross 
reactive antibodies with (Table 2-7) (43,45). Further examination of potential cross 
reactivity between IDV and historical ICV isolates appears warranted, although our data 
clearly show these two groups of viruses share common epitopes.  
 
Taken together, these data support, or at the least we cannot exclude, that the 
D/OK HI antibodies in the described human cohort were non-specific and instead due to 
cross reactivity with antibodies generated through prior, and perhaps repeated, ICV 
infection.  
 
 
Influenza C/D Virus Replication Kinetics in NHBE Cells 
 
To determine the relative ability of IDV to replicate in human cells we assayed 
the replication of D/OK, C/Victoria, C/Kowloon, and a classical human ICV derived   
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Figure 2-5. There is no statistical correlation between HI D/OK- and C/Victoria-
reactive antibodies from individuals from a rural farm community. 
The HI titers for D/OK and C/Victoria antibodies were compared for eight D/OK HI-
positive and six randomly selected D/OK HI-negative sera. D/OK HI positive sera are 
represented by red circles and negative sera are represented by black circles. The dotted 
lines denote the lowest HI titer to be considered positive. 
 
 
 
 
D/OK HI Negative
100
200
400
800
1600
3200
6400
100 200 400
D/OK HI Positive
D/OK ELISA Titers
C
/V
ic
to
ri
a
 E
L
IS
A
 T
it
e
rs
 
 
Figure 2-6. There is no statistical correlation of ELISA titers between D/OK- and 
C/Victoria-reactive antibodies of individuals which were D/OK HI positive. 
The ELISA titers for D/OK and C/Victoria antibodies were compared for eight D/OK HI-
positive and six randomly selected D/OK HI-negative sera. D/OK HI positive sera are 
represented by red circles and negative sera are represented by black circles. The dotted 
lines denote the lowest HI titer to be considered positive.  
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Figure 2-7. There is no statistical correlation of MN titers between D/OK- and 
C/Victoria-reactive antibodies of individuals which were D/OK HI positive. 
The MN titers for D/OK and C/Victoria antibodies were compared for eight D/OK HI-
positive and six randomly selected D/OK HI-negative sera.  D/OK HI positive sera are 
represented by red circles and negative sera are represented by black circles. The dotted 
lines denote the lowest HI titer to be considered positive. 
 
 
 
 
Table 2-4. There is no statistical correlation between D/OK and C/Victoria 
antibody titers as assessed by HI, ELISA, or MN. 
 
Statistical Value HI  ELISA  MN 
Spearman r 0.3633  0.1602  0.4425 
P value (two-tailed) 0.1518  0.5392  0.0753 
Significant? 
(alpha=0.05) 
no  no  no 
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Table 2-5. There is no statistical correlation between HI and MN titers for D/OK 
or C/Victoria. 
 
Statistical Value D/OK  C/Victoria 
Spearman r 0.006432  0.1965 
P value (two-tailed) 0.9805  0.4498 
Significant? 
(alpha=0.05) 
no  no 
 
 
 
 
Table 2-6. C/Victoria cRBC pre-adsorption of eight D/OK HI-positive sera 
removed previous D/OK HI antibody titers but A/Brisbane HI antibody titers were 
only reduced by 2-fold in another set of eight sera. 
 
Sample 
C/Victoria (HIU)  D/OK (HIU)  Sample A/Brisbane (HIU) 
Non-
treated 
Pre-
adsorbed 
 
Non-
treated 
Pre-
adsorbed 
 
 
Non-
treated 
Pre-
adsorbed 
1 160 20  40 0  9 0 0 
2 320 80  40 0  10 0 0 
3 80 0  40 0  11 80 40 
4 40 0  60 0  12 40 20 
5 320 0  60 0  13 0 0 
6 320 0  60 0  14 20 10 
7 160 160  40 20  15 10 0 
8 1280 160  40 0  16 20 10 
 
 
 
 
Table 2-7. HI cross-reactivity is not observed between IDV and ICV with 
polyclonal ferret sera as assessed by HI but is cross-reactive as assessed by MN and 
ELISA. 
 
Ferret Sera 
D/OK Antigen  C/Victoria Antigen 
HI ELISA MN  HI ELISA MN 
C/Victoria 0 260 0  320 6400 480 
D/OK 0 1120 5  0 6400 20 
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from reverse genetics for use in our reassortment assay described later, rg-C/JJ in NHBE 
cells (Figure 2-8).  All viruses replicated with titers of D/OK significantly higher than 
the human ICV at 48 and 120 hours post infection. When the area under the curve was 
calculated for each virus, D/OK demonstrated the most robust replication of all tested 
viruses: D/OK (515.2) C/Victoria (339.9), C/Kowloon (277.0), and rg-C/JJ (302.7). 
While there is no confirmed predictive value between growth in NHBE cells and 
successful infection of the human host, these data clearly demonstrate that there is no 
barrier to replication of IDV in human epithelial cells. 
 
 
Influenza C/D Virus Transmission in Ferrets 
 
Our in vitro assessment of D/OK replication in human cells supported a 
previously published in vivo assessment of zoonotic transmission in a ferret transmission 
model (43). Ferrets are used as a surrogate model of IAV infection due to similar disease 
pathology and transmissibility as that of human seasonal influenza viruses.  However, as 
no animal model has been established for the study of human ICV, we also explored the 
suitability of this model for classical human ICV transmission for comparison of D/OK. 
 
 To determine the relative fitness of IDV to infect and transmit in ferrets we 
assessed the replication, transmission, and seroconversion potential of D/OK and 
compared these profiles to infection with, C/Victoria, and C/Kowloon. Maximum virus 
shedding was achieved by day 4 post infection and all infections were cleared by day 6 
post infection as assessed by TCID50 of ferret nasal wash (Figure 2-9). Two of three 
ferrets infected with D/OK and one of three ferrets infected with C/Kowloon shed an 
average of log 1.5 TCID50/ml virus on day 4 post infection.  No viral shedding was 
detected from ferrets exposed to C/Kowloon by direct contact but all three ferrets 
exposed to D/OK by direct contact shed an average log 2.5 TCID50/ml virus titer.  Viral 
shedding was not detected in any C/Victoria infected or direct contact ferrets.  No clinical 
signs or symptoms were reported for any ferrets. HI was performed to determine 
seroconversion in ferrets 14 days post infection (Table 2-8). HI detectable antibodies 
reactive to D/OK were not identified in any donor or direct contact ferrets despite 
detection of viral shedding. Ferret seroconversion was detected in C/Kowloon donor and 
direct contact ferrets and C/Victoria donor ferrets indicating the ferrets are susceptible to 
C/Victoria despite lack of viral shedding from donor ferrets. Overall, data from virologic 
assays and serology were not robust and titers of viral shedding were low. Poor 
robustness of replication and the incongruence of serology and virus shedding in ferrets 
were confirmed in a repeat experiment. 
 
 
Influenza C and D Virus Reassortment 
 
Reassortment between animal and human IAV is a documented route for genesis 
of pandemic viruses. If IDV and ICV viruses were able to reassort, it is possible that 
viruses with enhanced zoonotic infection could be similarly generated. While classical 
reassortment studies have failed to detect IDV and ICV reassortants, we sought to   
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Figure 2-8. D/OK replicates to higher titers than human ICV in normal human 
bronchial epithelial cells. 
NHBE cells were infected at moi of 0 .01 with D/OK (blue circles), C/Victoria (pink 
squares), C/Kowloon (green triangles), and rg-C/JJ (black inverted triangles) and titers 
measured by TCID50 at 1, 24, 48, 72, 96, and 120 hours post-infection. The area under the 
curve for each virus was: D/OK (515.2), C/Victoria (339.9), C/Kowloon (277.0), and rg-
C/JJ (302.7). 
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Figure 2-9. D/OK and C/Kowloon are shed by inoculated ferrets but only D/OK is 
shed by direct contact ferrets. 
Viral shedding is reported as log10 TCID50 and the number of ferrets which shed 
detectable virus levels is reported above each bar. 
 
 
 
 
Table 2-8. ICV but not D/OK inoculated ferrets seroconverted. 
 
Virus 
Exposure 
Group 
Test Antigen 
D/OK C/Kowloon C/Victoria 
D/OK Donor 0   
Contact 0   
C/Kowloon Donor  640  
Contact  160  
C/Victoria Donor   160 
Contact   0 
 
Titers are represented as HIU. 
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force reassortment through a reverse genetics approach (45). Reverse genetics systems 
have been previously generated for IAV, IBV, and ICV and enable rescue of infectious 
virus from cell culture after transfection with the complete influenza genome encoded in 
multiple plasmids, each containing a different virus gene. This system can also be used 
for generation of reassortant viruses. Correspondingly, we generated a seven plasmid 
D/OK reverse genetics system using the pPMV cloning vector and protocol for rg-C/JJ 
(59). Effective rescue of wild-type reverse genetics D/OK virus (rg-D/OK) was followed 
by rescue of each rg-D/OK in context of a classical ICV virus, rg-C/JJ. In each case, 
D/OK genes were complementary to those of the classical ICV and reassortant viruses 
were recovered with comparable HA titers to that of rg-C/JJ at 7 days post transfection 
(Table 2-9). The composition of the rescued reassortant viruses was confirmed by Sanger 
sequencing demonstrating that, despite the minimal protein homologies, there are no 
general incompatibility issues interfering with successful IDV/ICV reassortment.  
 
The finding that IDV and ICV gene segments can reassort in an in vitro system 
has implications for the proposed classification of a novel genus. Indeed, reassortment of 
influenza viruses is dependent upon terminal noncoding regions of each RNA gene 
segment and compatibilities of protein functions and we demonstrate the ability to 
generate reassortant viruses containing IDV and ICV genes in vitro (19,32,60). However, 
this conflicts with a previously published study which failed to identify reassortants 
between IDV and ICV after co-infection (43). These discrepancies may be a consequence 
of the experimental method used and does not necessarily, in light of the antigenic and 
phylogenetic divergence between IDV and ICV discussed earlier, reflect compatibility of 
these two influenza types to reassort under natural conditions. 
 
It is important to note that the rescue of reassortant viruses discussed here were 
performed prior to implementation of the US Government moratorium on gain-of-
function influenza viruses, which will be discussed further in Chapter 3, and thus does 
not violate the moratorium. 
 
 
Discussion 
 
ICV are human respiratory pathogens which occasionally cross species barriers to 
infect swine (3,16). Unlike IAV, ICV lack an animal host reservoir and thus have never 
been considered to have pandemic potential. Therefore, the identification of a new 
subtype of ICV (or alternatively a new virus genus) antigenically distinct from circulating 
human strains with an altered host range (swine and cattle) is of particular public health 
interest. 
 
Since isolation in 2011, bovine IDV have been reported in the United States, 
France, and China and two phylogenetic clades have been identified suggesting extended 
circulation in the bovine population (43,45,48–52). Indeed, an estimated 88% 
seroprevalence of D/OK in surveyed cattle herds in the United States suggests that bovine 
IDV is well established (45). This estimate is supported by the 94% seroprevalence 
identified in neonatal calves in Mississippi (46).  This seroprevalence, along with our   
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Table 2-9. Average HA titer of rescued wild type and reassortant reverse 
genetics virus. 
 
Virus 
Virus Origin of Contributing Gene Rescue 
Titer PB2 PB1 P3 HEF NP M NS 
C/JJ C/JJ C/JJ C/JJ C/JJ C/JJ C/JJ C/JJ 6 
D/OK D/OK D/OK D/OK D/OK D/OK D/OK D/OK 64 
PB2 D/OK C/JJ C/JJ C/JJ C/JJ C/JJ C/JJ 5 
PB1 C/JJ D/OK C/JJ C/JJ C/JJ C/JJ C/JJ 4 
P3 C/JJ C/JJ D/OK C/JJ C/JJ C/JJ C/JJ 10 
HEF C/JJ C/JJ C/JJ D/OK C/JJ C/JJ C/JJ 16 
NP C/JJ C/JJ C/JJ C/JJ D/OK C/JJ C/JJ 8 
M C/JJ C/JJ C/JJ C/JJ C/JJ D/OK C/JJ 6 
NS C/JJ C/JJ C/JJ C/JJ C/JJ C/JJ D/OK 6 
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data showing that D/OK-like viruses have been in United States cattle since at least 2003, 
would strongly suggest that humans have been exposed to infected cattle providing a 
suitable environment for zoonotic transmission. There have, however, been no reported 
human cases of IDV and a previous surveillance study in a small cohort of individuals 
from Vancouver, Canada and Connecticut, United States identified only 1.3% 
seroprevalence in that general population. It is possible that, since surveillance has not 
targeted cattle in those geographic regions, that IDV does not circulate or has not 
circulated for sufficient time for evidence of infection to be found in the general 
population. We hypothesized that individuals with higher likely exposure might exhibit 
increased seroprevalence to IDV but our human serologic study only identified 1% of a 
cohort of individuals enriched (the study cohort was from a rural community in 
Wisconsin where many families were involved in dairy cattle enterprises) for cattle 
exposure with HI titers ≥40 to D/OK despite our finding of approximately 60% 
seropositivity of the cattle we surveyed in that state since 2003. We also consider it most 
likely that these individuals with seroreactivity to D/OK were not actually infected with 
the virus but rather had cross reactive antibodies likely generated by ICV infection. In the 
United States, 96% of adults, 20-30 years of age, possess antibody titers against human 
ICV (36). Supporting this conjecture, we carried out depletion studies where removal of 
ICV antibodies led to loss of the IDV HI titers in positive individuals. Results from 
earlier studies showed similar seropositivity rates of 1.3 % in the general population (43). 
If IDV does indeed cause frequent zoonotic infection we would have expected an 
elevated seroprevalence in our study population. 
 
Despite the lack of direct evidence for zoonotic infection, D/OK does possess 
properties that are consistent with an ability to infect humans. This includes the ability of 
D/OK to replicate in NHBE cells to a level that exceeds that of a set of human-adapted 
ICV and transmission by direct contact in ferrets, similar to that of a contemporary ICV. 
NHBE cells are commonly used as an in vitro model of the human upper respiratory tract 
and assessment of IAV infection (58,61,62). Further, ferrets are the in vivo model for 
assessment of transmission of IAV in humans (63–65). Neither NHBE cell replication 
nor the ferret transmission model have been validated for assessment of zoonotic 
potential of ICV but a previous study verified D/OK direct contact transmission in ferrets 
(43). In this study, we showed ferret transmission by direct contact, similar to a 
contemporary human ICV, although the titers of viral shedding were modest. However, 
the lack of robustness of the data from ferret serology and modest titers of ferret viral 
shedding would suggest that ferrets may not represent an adequate model for assessment 
of IDV or ICV transmission potential. Although directly inferring zoonotic infection 
potential from NHBE cell replication and ferret transmission might not be applicable, the 
fact that IDV can replicate in human primary epithelial cells argues that the possibility 
might exist. 
 
Avian influenza viruses replicate poorly in the human host yet have a documented 
ability to cause pandemics. The process by which avian viruses adapt to humans is 
enhanced by two properties of the virus, mutation caused by the error prone polymerase 
and by the ability for viruses to exchange genetic material through reassortment. Indeed, 
the 1957 and 1968 IAV pandemics were caused by reassortant viruses and if reassortment 
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between ICV and IDV were possible a similar route to IDV adaptation to humans could 
be considered. Reassortment of influenza viruses is determined by compatibilities of 
protein functions and terminal noncoding regions of each RNA gene segment and despite 
the 50% overall genome similarity of D/OK to that of human adapted ICV, the terminal 
noncoding regions differ by only a single nucleotide (11–13,15,43). Correspondingly, we 
were able to show robust generation of reassortant viruses when a reverse genetics 
approach was used to force reassortment. These data conflict somewhat with those of 
Hause and colleagues who were unable to generate natural reassortants after IDV/ICV 
coinfections (45). Differences in experimental approaches and ICV viruses used could 
underlie the different results but it is clear that IDV gene segments can readily 
complement those of ICV. Whether such reassortants impact zoonotic potential is 
unresolved. 
 
Taken together, our results provide further evidence for the widespread nature of 
IDV in cattle in the United States and, while there is no substantive evidence for human 
infection, IDV should be considered in workups of undiagnosed respiratory disease in 
individuals with exposure to cattle and other ruminants. 
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CHAPTER 3.    RECEPTOR TROPISM AND ESTERASE STABILITY OF IDV 
HEF RECEPTOR 
 
 
Introduction 
 
In Chapter 2 we assessed the zoonotic potential of a novel influenza virus, 
D/OK, the representative virus of a novel influenza genus that infects pigs, cattle, sheep, 
and goats. We showed that seroprevalence to D/OK in a cohort of individuals likely 
highly exposed to bovine pathogens was due to cross-reactive antibodies. While these 
data suggest that human infection with this virus is likely not high, D/OK does possess 
many of the characteristics commonly attributed to zoonotic potential of IAVs and may 
represent a zoonotic risk to public health. These two conflicting data sets suggest that if 
IDV were to become a common human pathogen-which it does not currently appear to 
be- it would likely need to undergo molecular adaptations similar to what is seen when 
avian IAV adapt to mammalian hosts. Based on the wealth of supporting literature from 
IAV, we hypothesized that a change in host range for IDV might be associated with 
changes in receptor preferences and perhaps biophysical characteristics. We therefore 
sought to examine IDV and ICV receptor usage and acid stability and, for the former, the 
underlying molecular determinants. 
 
The mechanisms which confer zoonotic potential, or, maintain host species 
barriers, are complex and not well understood. Studies have focused on IAV proteins, 
particularly HA and NA and host restriction of IBV and ICV has not been as readily 
addressed. This is of significance as ICV is the closest evolutionarily related genus to that 
of IDV, with 50% sequence homology across their whole genome and 53% or less 
homology in their HEF genes, similar to the sequence identity shared between IAV 
serotypes. We thus based our comparison of IDV and ICV host restriction upon 
mechanisms elucidated for IAV. 
 
The surface glycoproteins of influenza viruses contribute multiple functions in the 
virus infectious cycle including host cell receptor recognition/binding, viral and host cell 
membrane fusion for entry into the host cell, and receptor destroying function for 
budding of progeny virions. Each of these functions is essential for virus infection and 
correspondingly likely exhibits a role in host species restrictions (66–68). First, in order 
to facilitate binding of host cell receptors, the HA must first be activated by host enzyme 
proteolytic cleavage. This step can also contribute to host species restrictions based upon 
the compatibility of host proteolytic enzymes to the HA. Specifically, those IAV HA 
which contain a multi-basic cleavage site or lack an additional carbohydrate side chain 
near the cleavage site, are less restricted as to the specificity of proteolytic enzymes 
(66,69,70). The avian IAV strains possessing these characteristics, then, have 
demonstrated increased pathogenicity in human hosts. The proteolytic enzyme necessary 
for activation of ICV and IDV HEF is not known although the HEF polypeptide of both 
genera does exhibit a conserved monobasic cleavage site and crystal structure of both 
activated proteins confirms proteolytic cleavage (71). 
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The second mechanism of glycoprotein host restriction involves the recognition 
and binding of host cell sialic acids. The recognition and binding to host cell receptors by 
IAV HA is highly specific, differentiating between alpha 2,3- and alpha 2,6- linkages of 
sialic acids to galactose on the host cell which are expressed in a tissue and host species 
specific manner (65,72–76). Those IAV which specifically recognize and bind alpha 2,3- 
linked sialic acids, which are the predominant sialic acid species on the intestinal 
epithelia of avian hosts, predominately infect wild and domestic birds. Conversely, those 
viruses specific for alpha2,6-linked sialic acids, highly expressed on tracheal epithelia of 
the human respiratory tract, are associated with human-adaptation. Evolutionary 
adaptation which enables conversion of IAV receptor specificity from alpha 2,3- to alpha 
2,6- linked sialic acids is attributed to increased transmissibility of avian originating 
viruses in human hosts.  
 
The ICV glycoprotein utilizes O-type acetylated sialic acids to facilitate host cell 
binding and entry (28,30,77). Sialic acids can undergo O-type acetylation on either the 4 
or 9 carbon and ICV receptor recognition is highly specific to the position of the 
acetylated carbon atom. ICV HEF specifically binds 9-O-acetylated, but not 4-O-
acetylated, sialic acids and the crystal structure of ICV HEF was solved bound to 9-O-
acetylated sialic acid (30,78,79). Glycan arrays comparing IDV and ICV HEF receptor 
specificity have revealed higher binding affinity of IDV HEF than ICV HEF to 9-O-
acetylated sialic acids (71). Further, IDV HEF exhibits broader receptor tropism through 
binding of 9-O-acetylated sialic acid derivatives which ICV HEF does not bind. 
Comparison of the crystal structure of both proteins showed highly homologous overall 
structure but slightly altered conformation of the IDV HEF receptor binding moiety, in 
part due to an open channel formed by the absence of a salt bridge interaction between 
amino acid residues T239 and A273 (71). Slight conformational shifts seen in the IDV 
HEF binding cavity compared to ICV HEF may explain the altered receptor binding 
specificity and affinity of IDV HEF (43,71). 
 
The many orthomyxoviruses and coronaviruses which express acetylated sialic 
acid-binding surface glycoproteins, including ICV, IDV, mouse hepatitis virus, porcine 
torovirus, and human respiratory coronavirus OC43 and its proposed zoonotic ancestor 
bovine coronavirus, suggests widespread species distribution of acetylated sialic acids 
(43,80–82). However, the species and tissue distribution of acetylated sialic acids in 
mammals are largely unknown except for two studies only one of which included 
respiratory tissue(71,83). Using ICV and IDV esterase-null HEF probes for staining 
paraffinized sections, ICV and IDV receptors were detected on the apical surface of  
human, swine, and bovine trachea, although swine and bovine trachea had much brighter 
staining, suggesting the presence of 9-O-acetylated sialic acids (71). No publications 
were found concerning the species and tissue distribution of other acetylated 4-O-
acetylated sialic acids.  
 
The third mechanism of host restriction, once the influenza virion has undergone 
proteolytic cleavage and bound the host cell receptor, is to facilitate fusion of viral and 
host cell membranes. For IAV, the bound virion is endocytosed and a conformational 
change of the HA is triggered by decreasing pH of the maturing endosome. The 
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conformational alteration of the this protein is pH specific and this varies in different cell 
types and host species, which may confer host restrictions (69,84,85). Human-adapted 
IAV generally exhibit lower optimal pH of activation specificity than do avian IAV, as 
shown previously in a panel of human and avian IAV. In this study, human IAVs 
exhibited lower pHs of activation overall compared to avian IAVs (69). Adaptation 
leading to lowered pH of activation may be a contributing attribute to IAV pandemic 
potential. 
 
Extensive characterization of the ICV HEF protein has been performed in in vitro 
assays that assessed how membrane fusion and enzyme activity was affected by pH. 
Optimal esterase activity occurred between pH 7 and 8, with 50% enzyme activity 
retained when exposed to conditions as low as pH 5. Similarly, maximum fusion of 
liposomes in vitro occurs at pH 5.5, but the physiologic relevance is unknown (86). pH of 
activation may represent a mechanism of the HEF protein in host species restriction. 
 
The fourth mechanism of host restriction requires the enzyme specificity and 
activity of NA to correlate sufficiently with HA binding specificity (66,68). The NA 
exhibits a receptor destroying function necessary to allow progeny virions to properly 
bud from the host cell. If the NA receptor binding specificity and enzyme activity does 
not correlate to HA receptor specificity and affinity, the infectious cycle is impeded or 
delayed due to improper virion budding and may also contribute to host species 
restrictions.  
 
The HEF protein of ICV and IDV also exhibits receptor destroying activity via an 
acetylesterase domain. The ICV esterase specifically cleaves O-linked acetyl groups as 
assessed by its ability to hydrolyze only O-linked acetyl group containing compounds. 
The acetylesterase moiety of IDV HEF is highly structurally and functionally conserved 
to ICV HEF including homologous active site structure (43,71). Both ICV and IDV HEF 
utilize the esterase catalytic triad including amino acid residues S57, D356, and H359. 
Both enzymes exhibit receptor destroying activity even at 4oC. 
 
Last, a more general mechanism of viral host restriction involves temperature of 
viral replication. Avian IAV replication is adapted for replication at 40oC which 
corresponds to the temperature of avian intestinal tracts but replication in cell culture can 
also be observed at 37oC which corresponds to the lower human respiratory tract (87). 
However, 32oC, the temperature of the proximal human respiratory system is restrictive, 
possibly serving as a barrier to infection by avian IAV in humans. Conversely, ICV, 
which is widespread in humans, replicates optimally in cell culture at 33oC but is 
restricted at 37oC corresponding to higher expression of the HEF protein (88). IDV 
replication is not restricted at either temperature in cell culture (43). 
 
In this chapter, IDV receptor binding specificity, effect of temperature on 
replication kinetics, and pH of activation as compared to ICV is investigated as possible 
mechanisms of host species restrictions and barrier to zoonotic transmission of IDV. 
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Materials and Methods 
 
 
Cell Culture 
 
Swine testicle (ST), human rectal tumor 18G (HRT-18G), and human embryonic 
kidney 293T (293T) cells were obtained from the American Type Culture Collection 
(Manassas, VA). ST and HRT-18G cells were maintained in Dulbecco modified Eagle's 
medium (DMEM; Invitrogen Corporation, Grand Island, NY) and 293T cells were 
maintained in minimum essential medium (MEM; Corning, Manassas, VA), all media 
was supplemented with 5% fetal bovine serum (FBS; HyClone, Logan, UT) and 
antibiotics-antimycotic (Sigma, St. Louis, MO; 100 U/ml penicillin, 100 µg streptomycin, 
and 0.25 µg amphomycin per ml). All cell culture was incubated at 37oC and 5% CO2. 
 
 
Viruses 
 
In addition to the viruses listed in Materials and Methods of Chapter 2, the pH of 
activation assay used A/Tennessee/1-560/2009 (A/TN/09) stock supplied by Marion 
Russier and Charles Russell (St. Jude Children’s Research Hospital, Memphis, 
Tennessee). 
 
 
Virus Quantitation: Hemagglutination Assay 
 
Hemagglutination (HA) titers were determined by incubation of 2-fold, serially 
diluted virus with packed red blood cells (RBC) from various species at room 
temperature or 4oC. HA was performed using 0.5% chicken RBCs for 30 minutes and 1% 
horse, rat, sheep, pig, bovine, rabbit, guinea pig, and goat RBCs (Rockland Antibodies 
and Assays, Limerick, PA) for 60 minutes. HA titers were determined as the highest 
dilution to fully agglutinate the RBC. 
 
 
Virus Replication Kinetics 
 
Virus replication kinetics was performed in ST and HRT-18G cells.  Cells in 6-
well plates were infected with D/OK at a multiplicity of infection (moi) of 0.01 for 1 hour 
at 33oC or 37oC after which virus was replaced with infection media.  Samples were 
collected at 72, 120, and 168 hours post infection and stored at -80oC until titrated. Viral 
titers were reported as TCID50/ml.  The experiment was performed twice. 
 
 
Mutagenesis 
 
Single, double, and triple mutants of D/OK and C/JJ HEF proteins were prepared 
using the QuikChange® Site-Directed Mutagenesis Kit (Catalog #200518; 
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ThermoScientific, La Jolla, CA) according to manufacturer’s instructions. Briefly, the 
pPMV vector containing either D/OK or C/JJ HEF gene was used as the DNA template 
for standard protocol PCR using mutant specific primers and the subsequent PCR product 
was subjected to Dpn1 digestion prior to transformation to ensure transformation of 
mutant only clones. 
 
 
Viral-like Particle Expression 
 
293T cells were plated in 6-well plates at 37oC overnight. The following day, one 
microgram of each gene plasmid to be used was equilibrated with 16ul TransIT-LT1 
Transfection Reagent (Mirus, Madison, WI) in 200ul of Opti-MEM (Invitrogen 
Corporation, Grand Island, NY) for 45 minutes at room temperature. The transfection 
mixture was then brought to 1ml total volume and transferred to the 293T culture 
overnight at 33oC. On day 1 post-transfection; the inoculation media was replaced with 
1ml Opti-MEM supplemented with 200mM GlutaMAX supplement (Thermofisher 
Scientific, Carlsbad, CA) and antibiotics-antimycotics. On day 2 post-transfection; an 
additional 1ml transfection media with 1ug/ml TPCK was added to each transfection well 
at 33oC. On day 4 post-transfection; the culture supernatant was collected and HA titers 
of viral-like particles (VLPs) were determined with 0.5% chicken red blood cells. 
 
 
pH Inactivation Assay 
 
The pH inactivation assay was used to investigate pH stability of the influenza 
virion.  pH inactivation was assessed by exposure of each virus, standardized to 
equivalent HA titers based on the titer of the virus with lowest titer, to pH 3.0, 3.5, 4.5, 
5.0, 5.25, 5.5, 5.8, 6.0, 6.2, 6.5, or 7.0 at 37oC for 1 hour. Virus infectivity was then 
assessed by TCID50 in MDCKs. The assay was performed twice in replicate. 
 
 
Results 
 
 
D/OK Receptor Tropism 
 
Hemagglutination Specificity Assay. A hemagglutination assay using a panel of 
species specific RBC was used to determine if D/OK exhibited altered receptor 
specificity from ICV (Table 3-1). To compensate for varying concentrations of virus, the 
HA titers using RBC of the various species were normalized to the cRBC HA values, 
typically used in HA with ICV, and represented as a ratio to cRBC HA, where cRBC HA 
was represented as 1. No viruses agglutinated RBCs from guinea pig, goat, pig, bovine, 
or sheep at a detectable titer. Absence of detectable HA titer in sheep RBC was not 
surprising due to the absence of acetylated sialic acids on sheep RBCs. All three ICV 
agglutinated rat RBC to higher titers than cRBC as expected since a slightly higher 
percent of total rat RBC sialic acids are acetylated than cRBC. Conversely, D/OK   
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Table 3-1. IDV hemagglutination specificity differs from ICV. 
 
RBC Species 
 Virus  Acetylated Sialic Acid 
 D/OK C/Victoria C/Kowloon rg-C/JJ  Percent Position 
Chicken  1 1 1 1  20% C-9 
Rat  0.75 3 6 3  25% C-9 
Horse  2 1.5 2.5 1.5  20% C-4 
Guinea Pig  0 0 0 0  NK NK 
Goat  0 0 0 0  NK NK 
Pig  0 0 0 0  NK NK 
Bovine  0 0 0 0  NK NK 
Sheep  0 0 0 0  0% C-4 and 
C-9 
 
Values represent HA titer fold-change as compared to cRBC HA titer for each virus. NK 
indicates that percent or position of acetylated sialic acid is not known. 
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agglutinated rat RBC poorly compared to cRBC but agglutinated horse RBC, which 
expresses 4-O-acetylated sialic acids as the primary acetylated sialic acid species, to 
higher titer than cRBC. In summary, all ICV demonstrated preference to agglutinate 9-O-
acetylated expressing RBCs and D/OK preferentially agglutinated 4-O-acetylated 
expressing RBCs. 
 
Fold-change Analysis. The HA assay was optimized for comparison of viral 
receptor specificity by comparison of horse RBC and rat RBC HA titers by normalizing 
total titers to rat RBC titers for each virus (Table 3-2). Rat RBC HA titers of each ICV 
was higher than horse RBC indicating preference for 9-O-acetylated sialic acids but the 
HA titer of IDV with rat RBC was lower than horse RBC indicating preference for 4-O-
acetylated sialic acids. 
 
Use of VLP Instead of Virus. Several factors attribute to limitations of studying 
IDV and ICV receptor specificity. First, the most precise assay for studying influenza 
virus receptor binding specificity is through the use of a glycan array, which consists of a 
membrane coated with various species of sialic acid. This assay was not possible here as 
acetylated sialic acids were not commercially available and the core facilities at St. Jude 
Children’s Research Hospital were not equipped to produce them. Therefore, alternative 
methods for assessment of receptor tropism were needed. Second, the US Government 
moratorium on gain-of-function studies in all influenza viruses imposed a halt to any 
work which could be reasonably expected to increase transmission or pathogenicity of 
any influenza virus in mammals. The mutants we proposed to create for the study of 
receptor binding specificity would either alter receptor specificity of human-adapted 
ICVs to potentially increase specificity for bovine-like receptors or IDV to increase 
specificity for human-like receptors. The consequence of the resulting change in receptor 
specificity could be reasonably expected to increase transmission or pathogenicity of 
human-adapted viruses in cattle or bovine-adapted viruses in humans. In order to study 
receptor specificity of influenza viruses within the limitations of the moratorium, we 
attempted to create mutant virus-like particles (VLPs) expressing six of the seven total 
IDV or ICV genes. As VLPs are not replication competent, they do not violate the 
moratorium. VLPs were created by co-transfection of six of the seven reverse genetics 
plasmids for D/OK and C/JJ (the NS plasmid was omitted) and receptor binding 
specificity of the VLPs were compared to D/OK virus and rg-C/JJ. C/JJ VLP agglutinated 
rat RBCs to higher titers than horse RBCs, similar to rg-C/JJ virus. D/OK VLPs 
demonstrated different agglutination specificity from D/OK, which agglutinated horse 
RBCs to higher titers than rat RBCs, and agglutinated RBCs in a pattern similar to rg-
C/JJ (Table 3-3).  
 
Optimization of Hemagglutination Assay. Differential binding of D/OK VLP 
and D/OK virus required optimization of the VLP HA assay. The assay was performed at 
4oC and at room temperature for 1hr with both rat RBCs and horse RBCs to assess 
possible differences in esterase activity between D/OK VLP and D/OK virus. D/OK VLP 
HA titers were higher with horse RBCs than rat RBCs, similar to D/OK virus, at 4oC but 
not room temperature, suggesting that the different HA titer ratio between D/OK VLP 
and D/OK virus at room temperature was due to a difference in esterase activities.   
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Table 3-2. D/OK exhibits preference for horse RBC agglutination. 
 
RBC Species 
 Virus  Acetylated Sialic Acid 
 D/OK C/Victoria C/Kowloon rg-C/JJ  Percent Position 
Rat  1 1 1 1  25% C-9 
Horse  4 0.5 0.125 0.5  20% C-4 
 
Values represent HA titers for each virus as normalized to rat RBCs. 
 
 
 
 
Table 3-3. D/OK VLP do not exhibit the same HA specificity as D/OK virus. 
 
RBC Species 
(Position of Acetylated Carbon) 
Virus 
C/JJ VLP 
rg-C/JJ 
Virus 
D/OK VLP D/OK Virus 
Rat (C-9) 1 1 1 1 
Horse (C-4) 0.1875 0.125 0.3125 8 
 
Values represent HA titer fold-change as compared to rat RBC HA titer for each virus or 
VLP. 
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HEF Mutant Strategy. Computer modeling predicted three non-homologous 
amino acid residues in IDV HEF which may be contribute to altered receptor binding and 
esterase affinity of IDV compared to ICV (43). The IDV HEF amino acid residues 
proposed included 143, 201, and 256, which correspond to 141, 198, and 250 in ICV 
HEF (Figures 3-1 and 3-2). The 143 residue is located in the esterase domain and the 201 
and 256 residues are located in the receptor binding domain. We hypothesized that 
changes in these residues of IDV HEF could affect esterase and receptor specificity, 
contributing to the altered host range of IDV as compared to ICV. We mutated each of 
the three residues of an IDV representative virus, D/OK, alone or in combination, to the 
homologous residue in an ICV representative virus, C/JJ, and vice versa. Each single, 
double, and triple mutant was then expressed as a VLP along with wild type (WT) VLP 
and WT-reverse genetics virus (WT-rg virus) (Table 3-4). WT VLP was used as control 
for the mutant VLPs and WT-rg virus was used as control for the absence of the NS 
protein in the VLP. 
 
Expression and Quantitation of Mutant HEF VLP. Once optimized, rat RBC 
and horse RBC HA titers, as an indirect assessment of 9-O-acetylated and 4-O-acetylated 
sialic acids, respectively, of D/OK and C/JJ receptor binding mutant VLPs were 
determined compared to WT VLP, WT virus, and WT-rg virus (Tables 3-5 and 3-6). Due 
to concerns over using hemagglutination values to normalize virus amounts- we 
anticipated that mutants would have different avidities for RBC- ELISA was performed 
on all samples with polyclonal ferret anti-D/OK or anti-C/JJ antibodies and total virus 
normalized according to concentration. Mutant VLP F143Y and W201L decreased horse 
RBC titers but all three mutants increased rat RBC titers. C/JJ VLP mutants L198W and 
R250F increased horse RBC but decreased rat RBC titers whereas Y141F had no effect. 
Effect of Receptor Mutations on Hemagglutination Specificity. All D/OK VLP 
double mutants and the D/OK-Triple mutant completely ablated horse RBC HA titers but 
increased rat RBC HA titers over WT VLP and WT virus. For the C/JJ VLP mutants, 
Y141F/L198W increased rat RBC agglutination over WT VLP but Y141F/R250F and 
L198W/R250F decreased rat RBC agglutination (Figure 3-3a and b). Further, 
L198W/R250F increased horse RBC agglutination. However, the C/JJ-Triple mutant 
ablated agglutination of both horse RBC and rat RBC. Possible explanations of this lack 
of agglutination could be explained by altered tropism imposed by the specific mutations 
or  may be due to a reduction in overall conformational integrity of the receptor binding 
epitope of the C/JJ HEF or because the HEF protein was not incorporated, or 
insufficiently incorporated into the VLP.  
 
 
D/OK Replication Kinetics 
 
To assess preferential replication conditions of D/OK, we assessed replication in 
ST and HRT-18G cells. These cell lines were used to assess effect of temperature on 
replication in a cell line developed from the animal species D/OK was isolated from and 
a cell line developed from humans. We compared replication in both cell lines at 33oC 
and 37oC (Figure 3-4). D/OK replicated to highest titers in ST cells at 37oC and titers 
were significantly higher at 120 and 168 hours post infection at this condition. When the   
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Figure 3-1. The non-homologous amino acid residues proposed to affect receptor 
binding specificity of D/OK HEF reside in the receptor binding and esterase 
domains. 
Viruses included in alignment: D/OK, C/Ann Arbor/50 (C/AA), C/Johannesburg/1/66 
(C/JHB), and C/JJ. 
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Figure 3-2. Altered ligand orientation in the D/OK receptor binding site as 
predicted by computer modeling may contribute to altered receptor specificity. 
A) Superposition of D/OK (pink sticks) and C/JHB (gray sticks) esterase active site. The 
blue sticks represent the modeled orientation of a 9-O-acetylated sialic acid analog. B) 
Superposition of the receptor binding site of both viruses. C) Electrostatic model of 
surface of C/JHB receptor binding pocket with 9-O-acetylated sialic acid. D) Electrostatic 
model of the D/OK receptor binding pocket with 9-O-acetylated sialic acid. 
Reprinted with permission and under the terms of the Creative Commons Attribution 
Non-Commercial License. Hause BM, Ducatez M, Collin EA, Ran Z, Liu R, Sheng Z, et 
al. (2013) Isolation of a Novel Swine Influenza Virus from Oklahoma in 2011 Which Is 
Distantly Related to Human Influenza C Viruses. PLoS Pathog 9(2): e1003176. 
doi:10.1371/journal.ppat.1003176 
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Table 3-4. Strategy of receptor binding mutations. 
 
Virus Abbreviation Residue Mutation 
D/OK F143Y 143 F143 to Y 
 W201L 201 W201 to L 
 F256 R 256 F256 to R 
 F143Y/ W201L 143 and 201 F143 to Y and W201 to L 
 F143Y/ F256R 143 and 256 F143 to Y and F256 to R 
 W201L/ F256R 201 and 256 W201 to L  and F256 to R 
 
D/OK-Triple 143, 201, and 
256 
F143 to Y, W201 to L, and F256 to R 
C/JJ Y141F 141 Y141 to F 
 L198W 198 L198 to W 
 R250F 250 R250 to F 
 Y141F/ L198W 141 and 198 Y141 to F and L198 to W 
 Y141F/ R250F 141 and 250 Y141 to F and R250 to F 
 L198W/ R250F 198 and 250 L198 to W and R250 to F 
 
C/JJ-Triple 143, 201, and 
250 
Y141 to F, L198 to W, and R250 to F 
 
Note that the virus, representative of ICV, used here has been referred to as rg-C/JJ in this 
dissertation since it was originally rescued from reverse genetics and subsequently 
passaged in egg allantoic fluid to obtain sufficient stock. For clarity, in chapter 3, rg-C/JJ 
will be referred to as simply C/JJ virus and WT-rg C/JJ virus will be used to refer to 
rescued reverse genetics virus which was not subsequently passaged in egg allantoic 
fluid. 
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Table 3-5. Mutant receptor binding VLPs alter HA specificity of D/OK as 
compared to WT VLP and WT virus. 
 
Sample 
RBC Species 
(Position of Acetylated Carbon) 
Horse 
(C-4) 
Rat 
(C-9) 
D/OK WT VLP 4 0 
F143Y 2 16 
W201L 2 16 
F256R 4 8 
D/OK WT-rg 
Virus 
4 2 
D/OK Virus 16 1 
 
VLP particle concentration was normalized according to quantitation of total viral protein 
by ELISA with polyclonal antibodies. Total HA titers are reported. 
 
 
 
 
Table 3-6. Mutant receptor binding VLPs alter HA specificity of C/JJ as 
compared to WT VLP and WT virus. 
 
Sample 
RBC Species 
(Position of Acetylated Carbon) 
Horse 
(C-4) 
Rat 
(C-9) 
C/JJ WT VLP 0 1 
Y141F 0 1 
L198W 4 8 
R250F 2 4 
C/JJ WT-rg Virus 4 16 
C/JJ Virus 0 4 
 
VLP particle concentration was normalized according to quantitation of total viral protein 
by ELISA with polyclonal antibodies. Total HA titers are reported. 
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Figure 3-3. Double and triple receptor binding mutants have increased effect on 
HA specificity compared to single mutants. 
VLP concentration was normalized according to quantitation for total viral protein by 
ELISA with polyclonal antibodies. Total HA titers are reported. Horse RBCs expressed 
4-O-acetylated sialic acids and rat RBCs expressed 9-O-acetylated sialic acids. a) Results 
for D/OK VLP and mutants. b) Results for C/JJ VLP and mutants. 
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Figure 3-4. D/OK replication replicates to highest titers in ST cells at 37oC. 
ST and HRT-18G cells were infected at moi of 0.01 with D/OK and titers measured by 
TCID50 at 72, 120, and 168 hours post-infection. Replication kinetics was assessed in ST 
at 33oC (black line), HRT-18G at 33oC (blue line), ST at 37oC (green line), and HRT-18G 
at 37oC (pink line). The area under the curve for each condition was: ST at 33oC (617.5), 
HRT-18G at 33oC (567.5), ST at 37oC (771.6), and HRT-18G at 37oC (632.8). 
  
 50 
area under the curve was calculated for each condition, ST at 37oC was the condition 
which supported the most robust replication of D/OK: ST at 33oC (617.5), HRT-18G at 
33oC (567.5), ST at 37oC (771.6), and HRT-18G at 37oC (632.8). 
 
 
D/OK pH Sensitivity 
 
pH of D/OK inactivation and infectivity were assessed by comparison to an IAV, 
A/TN/09, in a pH inactivation assay (Figure 3-5). At pH 5.5 and below, infectivity of 
IAV was inhibited. D/OK infectivity did not decrease due to low pH treatment, 
suggesting that low pH may not trigger HEF fusion.  
 
 
Discussion 
 
The identification of a novel influenza genus, IDV, which shares at most 50% 
overall identity to ICV and exhibits an altered host range including an animal host 
reservoir reveals a zoonotic potential of the viruses classified in this genus. Further, IDV 
exhibits many of the characteristics generally attributed to zoonotic potential in IAV. The 
lack of direct evidence of IDV infection in humans presents the opportunity to investigate 
possible mechanism contributing to host species restrictions in IDV and impede zoonotic 
transmission. Several mechanisms of host species restriction have been attributed to the 
HA surface glycoprotein of IAV, which confers ability of zoonotic transmission from its 
numerous animal host species, and shares several similar functions to the HEF of IDV 
and ICV. Those zoonotic restrictions of IAV HA that may apply to IDV HEF include 
host receptor specificity, compatibility to host specific proteases, and optimal pH of virus 
activation which is compatible with specific host species. In this study, we investigated 
the possible role of host receptor specificity and pH of activation in the altered host range 
between IDV and ICV. 
 
To first determine receptor specificity of IDV in comparison to ICV, the 
hemagglutination specificity of D/OK and several ICVs were assessed using a panel of 
RBC from different species. In this assay, IDV and ICV agglutinated chicken, rat, and 
horse RBCs, as was expected based upon previously published data of acetylated sialic 
acid content for chicken, rat, and horse RBCs. Our analysis further compared 
agglutination of rat RBC and horse RBC by IDV and ICV. The preference of IDV to 
agglutinate horse RBC to greater titers than rat RBC indicates 4-O-acetylated sialic acids 
as the primary receptor of IDV, as compared to ICV which preferentially binds 9-O-
acetylated sialic acids. 
 
Based upon computer model predictions, three amino acid residue differences 
were identified which may contribute to the altered receptor specificity of IDV HEF 
compared to ICV and mutational analysis of those residues was proposed. Although 
expression of mutant viruses to assess these mutations were impeded due to the federally 
imposed gain-of-function moratorium, VLPs expressing those proposed residue 
mutations were created via a reverse genetics system in which six of the seven IDV and   
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Figure 3-5. D/OK infectivity is not affected by pH inactivation. 
Infectivity of each virus was determined as log10 TCID50/ml of virus after 5 days 
incubation at 33oC after inactivation at various pH. 
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ICV gene segments were co-expressed producing non-infectious VLPs. Expression of 
mutants as VLPs instead of infectious reverse genetics virus  required optimization of the 
HA assay since the VLP agglutination profile of D/OK differed from the D/OK virus but 
this was remedied by incubation of the assay at 4oC. The optimized HA assay of mutant 
VLPs revealed a role for each of the proposed amino acid residues in viral receptor 
tropism. Indeed, each single mutation expressing VLP reduced agglutination of the VLP 
preferred acetylated sialic acid expressing RBC, save for C/JJ Y141F, which did not alter 
agglutination from the WT VLP. The combination of double or triple mutations in D/OK 
VLP further increased agglutination of the non-preferred acetylated sialic acid expressing 
RBC. The C/JJ L198W/R250F VLP mutant followed this trend but C/JJ Y141F/L198W, 
Y141F/R250F, and triple mutant VLPs did not suggesting a more complex role of Y141F 
mutation in receptor specificity. These results suggest altered receptor binding specificity 
of IDV from ICV which may contribute to the altered host range of IDV. However, the 
contribution of this altered tropism is difficult to assess as the host and tissue distribution 
of acetylated sialic acids is largely unknown, save for a single study of 9-O-acetylated 
sialic acid immunohistochemistry in rat tissues, which did not include respiratory tissues. 
 
Another possible mechanism of host restriction which is relevant to IDV and ICV 
is temperature of the host respiratory system. The temperature of the human upper and 
lower respiratory tract is 32oC and 37oC, respectively, and ICV infection and diseases is 
generally restricted to the upper respiratory tract. This corresponds to optimal replication 
kinetics of ICV at 33oC in cell culture. Here, we demonstrate that 33oC, while not 
restrictive, is suboptimal to D/OK replication in certain cell lines and that replication in 
ST cells at 37oC was significantly higher at 120 and 168 hours post infection compared to 
other treatment groups. It may be that, if observation of in vitro replication kinetics 
corresponds to in vivo replication, IDV could effectively establish lower respiratory tract 
infections in humans once other zoonotic adaptations are acquired. 
 
In addition to the role of HEF receptor specificity the HEF pH of activation may 
also impose host species restrictions. Results in this study show that D/OK infectivity is 
not decreased by pre-exposure to pH values from 3.0 to 7.0, unlike a strain of IAV which 
is inactivated by exposure to pH 5.5 and lower. Despite the preliminary nature of the 
results, the experiment was repeated twice in triplicate adding strength to this 
observation. These results raise the unexpected finding that IDV infectivity is not 
affected by pH and that it may utilize a pH-independent pathway for host cell entry. This 
would be a unique trait for orthomyxoviruses and would be strong support for inclusion 
of this virus in a separate genus. This result should, however, be treated as preliminary 
and needs additional assays employed to confirm this observation. 
 
  Taken together, the results presented here suggest that the HEF protein of IDV 
exhibits altered receptor binding specificity from the HEF of ICV and optimal replication 
temperature and may contribute to a novel, pH-independent mechanism for host cell 
entry. Both unique features of this protein may contribute to the altered host range and 
zoonotic potential of IDV and should be further investigated in the interest of public 
health. 
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CHAPTER 4.    CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Conclusions 
 
A novel virus was isolated in 2011 from a swine exhibiting clinical respiratory 
symptoms in Oklahoma (43). Initial characterizations led to a classification as an ICV 
because it contains seven, negative-sense, single stranded RNA gene segments including 
a HEF gene segment.  The novel virus displayed 50% overall homology to that of human 
ICV and was antigenically distinct, which lead to the proposed classification as a new 
genus, IDV, and naming the representative virus D/OK, although this is a provisional 
designation (43,45).  
 
In addition to phylogenetic and antigenic divergence, D/OK also has an altered 
host range from ICV. Human ICV infects 60% of children by 4 years of age and exhibits 
only sporadic transmission across species barriers into swine populations (38,89), 
whereas D/OK has been isolated from swine and cattle but only 1.3% seroprevalence was 
identified in a human cohort of 316 individuals (38,43,45,89). Furthermore, sero-
surveillance has suggested that domestic sheep and goats are also hosts (47). Cattle are 
now believed to be the major reservoir for this virus due to high seroprevalence in the 
United States and the evolution of two phylogenetically and antigenically distinct clades 
represented by D/OK and, provisionally named, D/660 (45,46,48,49). Evidence of bovine 
IDV has also been reported in China, France, and Italy (50–52). 
 
 
Bovine Influenza Viruses Should Be Classified as IDV 
 
The antigenic and phylogenetic evidence supporting the classification of bovine 
influenza viruses as a novel genus is, as discussed in Chapter 1, consistent with the 
qualifications considered previously for influenza virus classification. IDV is 
antigenically diverged, as the predicted M (p42) and NP proteins of IDV exhibit less than 
40% amino acid identity to ICV proteins, and the PB1 protein of IDV, which is the most 
highly conserved of influenza proteins, shares only 72% identity with the closest related 
ICV. Although we present the observation of reassortment between recombinant IDV and 
ICV in this dissertation, this may not necessarily reflect compatibility of the two viruses 
to reassort in the event of a natural co-infection. In addition to terminal noncoding region 
compatibility, reassortment of two influenza viruses is also affected by the host-virus 
dynamic in which virus fitness and timing of infection in a specific host impacts 
reassortment (90–95). Though not permissible under the current US moratorium on 
influenza viruses, reassortant virus replication kinetics could provide additional insight 
into the functional compatibility of IDV and ICV proteins and fitness of reassortant 
viruses and the International Committee on Taxonomy of Viruses Orthomyxoviridae 
Study Group requested our in vitro reassortment data for consideration of IDV 
classification. Taken in consideration of these experimental limitations, while IDV and 
ICV noncoding regions support production of recombinant reassorant progeny, the 
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antigenic and genetic distances observed between IDV and other influenza genera is 
compelling and we propose official designation of a new orthomyxovirus genus, IDV.  
 
In practice, whether this virus is a new genus or not is really an academic 
question. We have provided evidence in this dissertation, and in published studies with 
collaborators, that it is clearly widespread in cattle and there is mounting evidence that it 
could well be associated with disease in this host (46,54). We can categorically state that 
IDV is a pathogen of multiple ruminants and other animals although much work is to be 
done to understand its impact in these hosts. Whether IDV represents a zoonotic threat is 
less clear although the data that we have generated and detailed below suggests that if it 
is human cases are rare but plausible. 
 
 
D/OK Is Widespread in Cattle with at Least Ten Years of Exposure Evident in the 
United States Population 
 
The widespread prevalence of D/OK in cattle for at least ten years provides 
evidence of probable human exposure to D/OK, particularly in those with frequent 
contact with cattle. Previously, a seroprevalence of 1.3% to D/OK was reported in a small 
cohort of 400 individuals with no reporting of prior exposure to cattle, prompting the 
hypothesis that individuals with higher exposure to bovine pathogens exhibit higher 
seroprevalence (43). We tested this hypothesis using a cohort consisting of over 700 
individuals greater than 50 years of age living in communities which would increase the 
likelihood of higher exposure to bovine pathogens. The age of the cohort was particularly 
relevant as the likelihood of seroconversion increases with increasing exposure. 
However, the serosurvey of this cohort did not reveal a seroprevalence greater than 1% 
prompting further serological analysis of the positive samples. HI titer of D/OK positive 
samples did not statistically correlate to HI titers of a contemporarily circulating ICV, but 
tended to be higher in the samples with higher ICV titers. Further, preadsorption of the 
sera with ICV prior to HI analysis of the samples abrogated the positive HI result to 
D/OK. These results suggest that seropositivity to D/OK is actually caused by cross-
reactive antibodies that were generated by a previous exposure to human ICV. 
 
Taken together, these results demonstrate that IDV is not highly infectious in 
humans, although work should be done to continue surveillance in highly exposed 
populations. Previous surveillance in feedlot cattle suggest younger cattle are highly 
susceptible to IDV infection and a cohort of individuals that work in feedlots or in the 
veterinary field may exhibit greater evidence of seroconversion (46). Further, 
seroprevalence is primarily assessed by inhibition of receptor binding by HA for IAV or 
HEF for IDV and ICV; however, in the case of IDV and ICV, the HEF protein exhibits 
both receptor binding and receptor destroying functions. Increasing evidence shows that 
antibodies reactive to NA of IAV may play a role in immune protection and future work 
should address the possibility that protective antibodies generated to IDV specifically 
target esterase and not receptor binding function (96–98). Last, it cannot be ruled out, due 
to existence of two antigenically distinct clades of IDV, that the population included in 
this study had been previously exposed to the antigenic clade not tested or that the cattle 
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those individuals had been exposed to were never infected by IDV. Future work should 
address both questions. 
 
 
D/OK Possesses Characteristics Generally Attributed to Zoonotic Potential and Can 
Reassort with ICV 
 
 Lack of direct evidence of D/OK infection in humans with likely exposure to 
bovine pathogens led us to question the zoonotic potential of IDVs. Addressing this 
question was somewhat problematic as the most similarly influenza genus, ICV, is 
primarily a human virus and no laboratory models exist for assessment of ICV zoonotic 
transmission. Thus, laboratory methods generally used to assess zoonotic potential of 
IAV were employed to assess IDV zoonotic potential and were simultaneously validated 
for use in the evaluation of ICV zoonotic potential. First, IDV and ICV replication 
kinetics were compared in NHBE cells, an in vitro model of the human upper respiratory 
tract used commonly in studies of IAVs. All ICVs assessed replicated in NHBE cells and 
D/OK replicated to statistically higher titers than the ICV at two time points. Therefore, 
D/OK could infect and replicate in human epithelial cells.  
 
Second, we compared the transmissibility of D/OK and ICVs in ferrets. Hause, et 
al. 2013 previously showed that D/OK does transmit via direct contact in ferrets and 
induce seroconversion in infected animals but it was impossible to determine the 
significance of these results since the ferret transmission model had never been assessed 
for ICV (43). In this study, shedding of C/Kowloon was detected in inoculated ferrets and 
direct contact ferrets seroconverted, which suggests transmission via direct contact, 
although viral shedding from direct contact ferrets was not detected. D/OK transmitted to 
direct contact ferrets, as seen previously, but no evidence of seroconversion was detected. 
The absence of ferret seroconversion after D/OK infection compared to C/Kowloon may 
have been due to the reduced titer of D/OK used for ferret inoculation compared to 
C/Kowloon. The protocol used to determine the titers of the C/Kowloon and D/OK stock 
viruses involved extending the incubation time by 48 hours before determining TCID50 
titers. Shorter incubation time in the previous study may have underestimated the D/OK 
titer, leading to a greater dilution of D/OK in our study to obtain the same infectious 
dose. If true, the D/OK ferret inoculum was of a lower titer compared to the C/Kowloon 
inoculum, and may have been sub-immunogenic. Indeed, although D/OK shedding was 
detected in inoculated and direct contact ferrets, the titers were lower than seen 
previously. Regardless the inconsistencies seen between the previously published study 
and the ferret transmission experiment discussed here, D/OK virus shedding was detected 
in direct contact ferrets for both studies. We also show that one of two human ICV likely 
transmitted by direct contact, as evidenced by seroconversion indicating that ferrets may 
be a useful model for IDV/ICV zoonotic transmission.  
 
The NHBE replication kinetics and ferret transmission studies presented here 
demonstrate IDV replication and transmission characteristics equal to or higher than the 
assessed ICV. However, the implications of these results do not necessarily indicate 
increased zoonotic potential of IDV since little is known about ICV pathogenicity and 
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transmission and validated models for such assessment do not exist. The results do 
demonstrate that D/OK does exhibit some of the characteristics generally attributed to 
zoonotic potential for IAV.  
  
In light of possible IDV zoonotic potential, further consideration for the 
possibility of IDV reassortment with ICV was addressed. Reassortment of IDV and ICV 
was attempted in a previous study by another research group using an in vitro co-
infection model but this study failed to identify reassortant progeny. This was surprising 
as compatibility of influenza gene reassorment is largely determined by the 
complementarity of the terminal, noncoding ends and, for IDV and ICV, there is only a 
single nucleotide difference in these regions. Here, reassortment potential is addressed by 
rescue of reassortant viruses using a reverse genetics system. This study demonstrated 
that each of the seven rg-D/OK genes could be rescued in the context of a rg-C/JJ virus 
indicating that, if zoonotic transmission of IDV is achieved, co-infection by IDV and ICV 
could yield reassortant progeny with increased transmissibility. 
 
 
D/OK May Possess Altered Host Restrictions from ICV 
 
 Lack of evidence of IDV infection in humans, despite exhibiting characteristics 
attributed to zoonotic potential in IAV, suggests that mechanisms exist that maintain 
species barriers for IDV. While the mechanisms which impose species restrictions on 
influenza viruses are highly relevant to public health, they are not well understood. For 
IAV, the surface glycoproteins have been implicated, including host receptor specificity 
and pH of activation.  The possible role of these mechanisms in IDV host restriction was 
assessed by comparison to ICV. The surface glycoprotein of ICV and IDV, HEF, was 
assessed for receptor binding specificity by HA using RBCs from various animal species. 
These experiments revealed a preference of IDV for agglutination of 4-O-acetylated 
sialic acid-rich RBCs compared to ICV, which preferentially agglutinated 9-O-acetylated 
sialic acid-rich RBCs. Previously published computer modeling predicted that three non-
homologous amino acids in the receptor binding domain of the IDV and ICV HEFs 
would alter receptor binding. Ideally, the significance of these amino acids would have 
been assessed in mutant viruses. However, the current moratorium on gain-of-function 
studies precluded such an experiment. Instead, it was necessary to create non-infectious 
virus-like particles (VLPs) using six of the seven ICV or IDV reverse genetics plasmids 
containing these mutations.  
 
Initial expression of VLP required some troubleshooting as the agglutination 
profile of IDV VLP differed from that of IDV virus. There are many possible 
explanations for this difference, including altered HEF incorporation into the VLP, 
altered VLP morphology, or altered HEF glycosylation due to propagation of virus in ST 
cells and rescue of VLP in 293T cells. These differences could result in altered receptor 
binding or esterase activity leading to the observed differences in agglutination profile 
between IDV VLP and virus.  Ultimately, the altered agglutination profile was remedied 
by incubation of the assay at 4oC indicating that esterase activity was likely the cause of 
this difference although protein conformation may also be affected by the lowered 
 57 
temperature. The cause of altered VLP agglutination could be further addressed via use of 
an HEF inhibitor, diisopropyl fluorophosphate, in the agglutination assay which would be 
expected to restore VLP agglutination to that of the virus agglutination profile by 
reducing cleavage of the IDV receptor on RBCs. Alternatively, various techniques 
including electron microscopy, Western blotting, or coumassie staining of total viral 
protein would provide a comparison of virion and VLP morphology and HEF 
incorporation which could also contribute to the altered VLP agglutination profile. 
 
After optimization of the VLP assay, which revealed a likely difference in 
esterase activities between the IDV VLP and IDV virus, we tested the impact of the 
aforementioned mutations in the D/OK VLPs. Individually, these mutations increased the 
agglutination of RBCs that were not ‘preferred’ previously. Introduction of two or three 
of these mutations further decreased agglutination of the preferred RBC species. The 
results of the VLP assays suggested that the predicted amino acids do influence the host 
receptor specificity of IDV and ICV. Indeed, conversion of combinations of the IDV 
amino acid residues to be homologous to ICV residues altered receptor binding to be 
more “ ICV-like” and vice versa. A natural extrapolation of these data would suggest that 
a similar phenomenon applies to IDV and ICV host range as seen in IAV where receptor 
distribution is central to virus host partnerships. One could hypothesize that human 
respiratory tissues lack the 4-O-acetylated sialic acids needed for infection by IDV and, 
thereby, providing a mechanism for the lack of frequent human infection inferred from 
our serologic studies. Such a hypothesis could be readily tested by closer examination of 
4-O-acetylated sialic acids lining the bovine and human respiratory tracts. It would 
further be of interest, though not permissible under the conditions of the current US 
moratorium, if the mutant HEF of both viruses would contribute to altered fitness of 
infectious virus in cell culture or an animal model such as ferrets or guinea pigs. 
 
 Another aspect of host restriction for IDV addressed optimal temperature 
conditions for replication. Avian IAV replication is adapted for replication at 40oC which 
corresponds to the temperature of avian intestinal tracts but 32oC, the temperature of the 
proximal human respiratory system is restrictive, possibly serving as a barrier to infection 
by avian IAV in humans. We show that, in cell culture, IDV replicates to relatively high 
titers at both 33oC and 37oC, the higher temperature associated with the human lower 
respiratory track suggesting that IDV infectivity would not be restricted by temperatures 
of the proximal human respiratory system. It is possible that the in vitro observations 
made in this study are not conferred to in vivo conditions; however, temperature 
restrictions of ICV in cell culture do correspond to the restriction of ICV to primarily 
upper respiratory infections caused in humans. Comparison of replication kinetics in 
human primary cells such as NHBEs or tissue explants from upper and lower respiratory 
tracts at both 33oC and 37oC would add to interpretation of these findings. 
 
The pH of inactivation of IDV was also compared to IAV in a preliminary 
experiment to determine total virus infectivity after exposure to buffers of varying pH. 
The results suggest that IDV infectivity is not decreased by exposure to pH ranging from 
3.0 to 7.0, in contrast to IAV. This data, albeit very preliminary, raises the unexpected 
suggestion that IDV replication is pH independent. However, further experimentation 
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will need to be conducted in order to confirm this pH independent mechanism. It is 
possible that exposure to low pH does indeed induce a conformational change of the IDV 
HEF but that it is a reversible change and returning the virion to neutral pH for infection 
reverses the pH-induced inactivation.  This possibility would be addressed 
experimentally with the use of pharmacological agents to raise endosomal pH, including 
bafilomycin A, a vacuolar H+-ATPase, and monensin, a carboxylic ionophore (99). If 
IDV does utilize a pH independent mechanism of cell entry IDV infection would not be 
affected by use of these pharmacological agents. Ammonium chloride is another possible 
reagent for assessment of pH independent cell entry although it induced conformational 
changes to the HA of IAV during cell surface transport and packaging. Ammonium 
chloride could be evaluated for use with IDV and ICV. Additional assays including pH 
syncytia formation and pH of activation should also be optimized to confirm the 
observation that IDV utilizes a pH independent mechanism of cell entry. If this 
observation is confirmed, it would be a first for this family of viruses and is an area that 
needs to be vigorously explored. It has become clear in recent years that HA stability in 
IAV is an underappreciated factor contributing to host range (69,84). The preliminary 
observation of a pH-independent mechanism of IDV infectivity could prove very 
valuable to understanding IDV infectious cycle and host species restrictions. 
 
 
Continued IDV Assessment and Surveillance for Public Safety 
 
The widespread exposure of the United States population to IDV in cattle 
necessitates continued surveillance of IDV in America and across the globe.  Particularly, 
expanded sero-surveillance should be conducted in the countries of South America, with 
respect to the single identification of D/OK seroprevalence in Chile, to better understand 
worldwide exposure and risk posed to the human population. Expanded studies should 
also include surveillance of both identified phylogenic/antigenic lineages of bovine IDV 
for a more complete assessment of prevalence in cattle and risk to humans. Additionally, 
with respect to low seroprevalence and cross-reactivity of HI antibody titers in our human 
cohort, it may be that IDV is not immunogenic in humans or that neutralizing antibodies 
generated in response to IDV infection are not inhibitory to receptor binding and thus not 
detectable by HI or MN. Alternative assays may better detect IDV neutralizing 
antibodies, specifically esterase inhibition assays. Finally, the low seroprevalence seen in 
our human cohort could be explained by the cross-reactivity of human IDV directed 
antibodies. IDV may zoonotically transmit but the high seroprevalence of ICV in humans 
and cross-reactivity of ICV generated antibodies may provide protection against IDV 
established infections. Results of a ferret IDV challenge would be interesting in light of 
our sero-surveillance data. 
 
The assessment of zoonotic potential of IDV in this study is based upon current 
laboratory models commonly used for assessment of IAV zoonotic potential. They may 
not represent optimal methods for assessment of zoonotic potential of ICV or IDV. 
Specifically, we were not able to detect direct contact transmission of one of our human 
ICV in our ferret study and no ferrets demonstrated clinical signs due to virus infection in 
that experiment. Additionally, a previous study was not able to detect IDV replication in 
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laboratory inoculated ferret tissues. Validation of the ferret model for IDV and ICV 
zoonotic transmission, specifically viral replication competence in ferret respiratory 
primary cell culture and tissue, would contribute further support of the conclusions 
presented here. Another laboratory model for consideration, guinea pigs, has 
demonstrated IDV transmission by direct contact, with detection of virus in nasal 
turbinates and lung tissues. Guinea pigs may be a better animal model for IDV 
transmission studies and should be evaluated for such use in comparison to ICV 
transmission. 
 
Determination of the possible receptor binding specificities of IDV that differ 
from ICV may be valuable concerning host range and adaptations necessary for zoonotic 
transmission of IDV. Additional and more precise experimentation needs to be conducted 
to confirm the receptor specificity of IDV, specifically, acetylated sialic acid binding 
arrays with IDV and ICV. Additionally, expanded assessment of acetylated sialic acid 
expression in bovine and human respiratory tissues, including lung tissues, by 
immunohistochemistry would greatly enhance the understanding of the role of receptor 
specificity in host barriers of IDV. If the specific evolutionary changes necessary to 
increase zoonotic transmission of IDV via receptor specificity are determined, this will 
lend to more effective surveillance efforts for the detection of zoonotic IDV. 
 
Addressing the aspects of temperature restriction on IDV replication will add to 
further understanding of IDV host restriction and zoonotic potential. Exposure to ICV is 
widespread in humans and infections are primarily restricted to the upper respiratory 
track although lower respiratory tract infections and hospitalizations do occasionally 
occur. No studies, however, have elucidated whether specific mutations are acquired by 
ICV to enable replication in the human lower respiratory tract. A study of ICV-associated 
infections leading to hospitalization could reveal the mutations, if any, which contribute 
to more severe disease caused by ICV and could be used to better inform surveillance 
efforts for detection of zoonotic IDV. 
 
Finally, if IDV indeed enters the host cell via a pH independent mechanism, the 
very exciting opportunity is presented to elucidate a novel mechanism for 
orthomyxovirus host cell entry. Further experimentation will be needed to consider the 
possibility that IDV utilizes receptor-mediated endocytosis followed by pH-independent 
fusion, fusion at the plasma membrane and disassembly of the cell’s actin cortex, or 
another novel mechanism (100,101). Various reagents and assays are available to fully 
evaluate IDV mechanism of cell entry. It would seem likely that, given the general 
structural homology of IDV to other influenza genera including a predicted M2 
polypeptide, IDV utilizes the endocytic transport pathway for virion uncoating and cell 
entry despite that HEF induction of membrane fusion is not pH dependent. Amantadine is 
an antiviral which acts via a mechanism of IAV M2 inhibition and, although specific to 
IAV M2 and not effective against IBV, could be evaluated for use with IDV and ICV ion 
channel proteins represented by the P42 polypeptide (102). Results from use of 
amantadine would be expected to inhibit IDV infection. Another caveat to study of pH 
independent cell entry is elucidated by filoviruses such as Ebola, which were previously 
believed to utilize a pH independent mechanism of cell entry, in part, because Ebola 
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infectivity was not inactivated by low pH. Ebola is now known to require pH induced 
conformational change prior to subsequent cleavage by endosomal cysteine proteases 
(103,104). This may not be the case for IDV considering the crystal structure of the 
ligand-bound IDV HEF is in a cleaved confirmation; however, there are a myriad of 
specific protease inhibitors which would be expected to reduce IDV infection in an 
inhibitor-specific manner if this is the mechanism utilized by IDV (71). Once identified, 
pre-incubation with said protease, with or without previous pH exposure, or deletion of 
the protease target sequence would also inhibit IDV infection and further validate IDV 
pH independent cell entry. Last, various assays to determine if IDV enters the host cell 
via clathrin/caveolin-mediated endocytosis, clathrin/caveolin-independent endocytosis, or 
macropinocytosis/phagocytosis can be used. Inhibitors such as dynasore block 
clathrin/caveolin-mediated endocytosis via inhibition of dynamin activity but not 
clathrin/caveolin-independent pathways (105). Inhibition of IDV infection using 
dynasore or related inhibitor would indicate use of clathrin/caveolin mediated 
endocytosis. Further, cytochalasin D, which inhibits actin polymerization, inhibits 
phagocytosis and macropinocytosis due to inability to rearrange the actin cytoskeleton 
(106,107). IDV infection inhibition by cytochalasin D but not dynasore would indicate 
possible entry by macropinocytosis or phagocytosis. Use of these and/or related inhibitors 
can assist to tease out the mechanism of IDV cell entry. 
 
If IDV replication is indeed pH independent it would represent a remarkable 
evolutionary distinction from IAV. What factors led to differential entry mechanisms of 
IVD and IDV may provide further insight into the mechanism of host range differences 
between the two. 
 
 
Summary 
 
The study outlined in this dissertation reveals that IDV is widespread in cattle in 
the United States, with zoonotic exposure to the US population over a period of at least 
ten years. IDV is also present in South America. While there is no direct evidence of 
human infections, IDV does possess characteristics attributed to zoonotic potential of 
IAV. However, host receptor specificity, a characteristic believed to contribute to the host 
restriction of IAVs, may contribute to the species barriers of IDV. Further, IDV may 
utilize a pH-independent mechanism for host cell entry, unique from other influenza 
viruses. IDV may present a zoonotic risk and should continue to be monitored in cattle 
and human populations while continued studies of the mechanisms which confer host 
barriers are assessed. 
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